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Abstract  
Objective: Parkinson’s disease is a progressive neurodegenerative disorder 
characterized by the presence of motor symptoms and a variety of non-motor 
symptoms. The ability to recognize facial emotion expressions, a skill of great 
importance for non-verbal communication and social interaction, has been reported 
to be impaired in Parkinson’s disease, yet, previous studies showed inconsistent 
findings. The orbitofrontal cortex, the anterior cingulate, the amygdala, the basal 
ganglia, temporoparietal areas and visual processing areas seem to constitute crucial 
neural substrates of the ability to recognize facial emotions. The aim of this study 
was to further investigate facial emotion recognition in Parkinson’s disease patients 
and its’ association with demographic and clinical parameters (including motor and 
non-motor symptoms). As facial emotion recognition and olfaction, a known non-
motor symptom of the disease, could share common neural substrates, we tested 
whether there is an association of facial emotion recognition and olfaction.  
Patients and methods: Thirty-four non-demented Parkinson’s disease patients and 
24 frequency age- and sex-matched healthy controls underwent clinical neurological 
and neuropsychological assessment including the Beck Depression Inventory, the 
Apathy Evaluation Scale, the Rapid Eye Movement sleep Behavior Disorder Screening 
Questionnaire, the Parkinson neuropsychometric dementia assessment  instrument 
and the cognitive estimation test, standardized olfactory testing with Sniffin’ sticks 
and the Ekman 60 Faces Emotion Recognition Test. The groups did not differ with 
respect to mini mental state examination score and education.  
Results: Parkinson’s disease patients had a significantly lower score on the total 
facial emotion recognition task in comparison with healthy controls (F=8.030, 
p=0.006), even after controlling for the potential confounding factors depression and 
apathy.  The Parkinson’s disease group had a specific impairment in the recognition 
of surprise (F=7.885, p=0.007). The recognition of anger approached statistical 
significance (p=0.07). The emotion more accurately recognized by both groups was 
happiness while fear was less accurate recognized also by both groups. The most 
common misattributions of emotions in both groups were: happiness as surprise, 
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sadness as fear, fear as surprise, disgust as anger and surprise as fear. Increasing 
chronological age (β=-0.294, p=0.001, CI 95% -0.462, -0.126) and age at disease 
onset (β=-0.194, p=0.012, CI 95% -0.342, -0.046) were associated with worse 
performance on the facial emotion recognition task in Parkinson’s disease patients. 
Worse olfactory function along with Parkinson’s disease diagnosis predicted worse 
facial emotion recognition performance within all study participants. Facial emotion 
recognition was not associated with patients’ characteristics like gender and 
education or disease characteristics like disease disability, motor impairment, 
disease duration, disease severity, disease most affected body side, type of 
Parkinson’s disease, hypomimia, freezing of gait, postural instability, orthostatic 
dysregulation and Rapid Eye Movement sleep behavior disorder. In addition, facial 
emotion recognition was not also predicted by global cognitive performance, 
executive functions like performance on the cognitive estimation task, depression or 
apathy. 
 
Conclusion: Facial emotion recognition and especially the recognition of surprise are 
significantly impaired in Parkinson’s patients compared with age- and sex-matched 
healthy control individuals. The association of facial emotion recognition with age 
(chronological age and age at disease onset) and olfactory function is endorsed by 
common structures that undergo neurodegeneration in Parkinson’s disease. 
Impaired facial emotion recognition in Parkinson’s disease may rely on anatomical 
connections of the basal ganglia, which appear to play a role in recognizing emotions 
from facial cues, as part of a distributed network of cortical and subcortical 
structures or may reflect a dysfunction of the cortical-basal ganglia-thalamic-cortical 
functional loops. The relevance of facial emotion recognition in social interaction 
stresses the clinical relevance and the need for further investigation in this field. 
Future studies should also determine whether impaired facial emotion recognition is 
already present in premotor stages of Parkinson’s disease. It seems necessary to 
integrate tasks accessing facial emotion recognition in clinical practice in order to 
evaluate this non-motor aspect of the disease that can affect patients’ social 
behavior in order to appreciate the full extent of deficits of patients and to provide 
an adequate treatment in Parkinson’s disease. 
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Zusammenfassung 
Demographische und klinische Faktoren assoziiert mit gestörter 
Gesichtsemotionserkennung in M. Parkinson 
Einleitung: Morbus Parkinson ist eine progressive neurodegenerative Erkrankung, die 
durch das Vorliegen von motorischen und nicht-motorischen Symptomen 
gekennzeichnet wird. Die Fähigkeit Emotionen in Gesichtern zu erkennen, eine 
Fertigkeit von großer Bedeutung für die non-verbale Kommunikation und soziale 
Interaktion scheint beim Morbus Parkinson gestört zu sein, vorherige Studien haben 
diesbezüglich allerdings widersprüchliche Ergebnisse gezeigt.  Der orbitofrontale 
Kortex, der anterioriore cinguläre Kortex, die Amygdala, die Basalganglien, 
temporoparietale und visuell verarbeitende Areale stellen die neuronalen Substraten 
der Emotionserkennung in Gesichtern dar. Das Ziel der Studie war  die 
Emotionserkennung in Gesichtern in Patienten mit Morbus Parkinson weiter zu 
erforschen und mögliche Assoziationen mit demographischen und klinischen 
Faktoren (motorischen und nicht motorischen Symptomen) zu evaluieren. Da die 
Emotionserkennung und der Geruchssinn, ein bekanntes nicht-motorisches Merkmal 
der Krankheit, in denselben neuronalen Substraten angesiedelt sind, haben wir auch 
untersucht, ob eine Assoziation zwischen Emotionserkennung und Geruchssinn 
besteht.    
Matherial und Methodik: Vierunddreißig Patienten mit Morbus Parkinson und 24 
gematchte gesunde Personen wurden klinisch, neurologisch und neuropsychologisch 
mit Hilfe des Beck Depression Inventars, der Apathie Evaluation Skala, dem Rapid 
Eye Movement-Schlaf-Verhaltensstörung Fragebogen, dem Parkinson 
neuropsychometric dementia assessment Test, dem Test zum kognitiven Schätzen, 
eines standarisierten Geruchtstest Sniffin’ sticks und des Ekman 60 Faces Tests zur 
Emotionserkennung untersucht. Es gab keine Abweichungen zwischen den beiden 
Gruppen bezüglich des mini-mental Status und Ausbildungsstatus. 
Ergebnisse: Patienten mit Morbus Parkinson hatten eine signifikant niedrigere 
Leistung im Emotionserkennungtest (F=8.030, p=0.006) im Vergleich zu den 
gesunden Personen, auch nach Berücksichtigung der potentiellen Störfaktoren 
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Depression und Apathie. Die Parkinson Patienten wiesen eine gestörte 
Emotionserkennung der Emotion Überraschung auf (F=7.885, p=0.007). Die 
Erkennung der Emotion Wut näherte sich der statistische Signifikanz an (p=0.07). Die 
Emotion, die am häufigsten richtig erkannt wurde, war Freude, während Furcht von 
beiden Gruppen am schlechtesten erkannt wurde. Die in beiden Gruppen am 
häufigsten vorkommende Fehlzuschreibung von Emotionen waren: Freude als 
Überraschung, Traurigkeit als Furcht, Furcht als Überraschung, Ekel als Wut und 
Überraschung als Furcht. Zunehmendes Alter (β=-0.294, p=0.001, CI 95% -0.462, -
0.126) und Alter des Patienten bei Beginn der Erkrankung (β=-0.194, p=0.012, CI 95% 
-0.342, -0.046) waren mit einer schlechteren Leistung der Emotionserkennung bei 
Parkinson Patienten assoziiert. Verminderter Geruchssinn einhergehend mit der 
Diagnose eines Morbus Parkinson konnten eine schlechtere Leistung zwischen allen 
Studie Teilnehmern voraussagen. Die Emotionserkennung war nicht assoziiert mit 
Eigenschaften der Patienten wie Geschlecht und Ausbildung oder mit Eigenschaften 
der Erkrankung wie krankheitsbedingte Behinderung, motorische Einschränkungen, 
Dauer der Erkrankung, der am stärksten betroffenen  Körperseite, Parkinson Typ, 
Hypomimie, Freezing beim Gehen, posturale Instabilität, orthostatische 
Dysregulation und Rapid Eye Movement-Schlaf-Verhaltensstörung. Ferner konnte 
die Emotionserkennung mit der globalen kognitiven Leistung, exekutiven Funktionen 
wie kognitives Schätzen, Depression oder Apathie nicht assoziiert werden. 
Schlussfolgerungen: Emotionserkennung in Gesichtern und besonders die Erkennung 
der Emotion Überraschung sind bei den Parkinson Patienten signifikant gestört im 
Vergleich zu alters- und geschlechts- gematchten gesunden Personen. Der 
Zusammenhang der Emotionserkennung und des Alters und Alters des Beginns der 
Erkrankung sowie der Emotionserkennung und des Geruchssinns ist durch 
gemeinsame Strukturen, die eine Neurodegeneration in der Parkinson Krankheit 
durchmachen, zu erklären. Die gestörte Emotionserkennung beim Morbus Parkinson 
könnte von anatomischen Verbindungen der Basalganglien abhängen, die vermutlich 
eine Rolle bei der Emotionserkennung von Gesichtermerkmalen spielen, als Teil von 
einem verbreiteten Netzwerk von kortikalen und subkortikalen Strukturen. Des 
Weiteren könnte sie eine Funktionsstörung der kortiko-Basalganglien-thalamische-
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kortikalen funktionellen Schleifen widerspiegeln. Die Bedeutung der Erkennung von 
Emotionen in Gesichtern bei den sozialen Interaktionen betont die klinische 
Bedeutung dieser Funktion und den Bedarf an weiterer Forschung in diesem Bereich. 
Zukünftige Studien könnten untersuchen, ob eine gestörte Emotionserkennung 
sogar in den prämotorischen Stadien der Erkrankung vorhanden ist. Es ist notwendig, 
dass Emotionserkennungsaufgaben im klinischen Alltag integriert werden, um diesen 
nicht-motorischen Aspekt der Erkrankung, der das soziale Verhalten des Patienten 
beeinflussen kann, evaluieren zu können und eine adäquate Behandlung der 
Patienten mit Morbus Parkinson leisten zu können. 
Schlüsselwörter: Morbus Parkinson, Emotionserkennung, nicht-motorische 
Symptome, Geruchssinn, Alter 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Demographic and clinical factors associated with impaired facial emotion 
recognition in Parkinson’s disease 
1. Introduction 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized 
by the presence of motor symptoms including bradykinesia, rigidity, resting tremor 
and postural instability. Other typical motor features are hypomimia (masked face or 
reduced facial expression), shuffling gait and micrographia. PD is also characterized 
by a variety of non-motor symptoms including autonomic dysfunction (like 
orthostatic hypotension, bladder disturbances, constipation, sweating and sexual 
dysfunction),  sleep disorders (like sleep fragmentation, insomnia, excessive daytime 
sleepiness, rapid eye movement sleep behaviour disorder and restless legs or 
periodic limb movements), sensory disorders (like olfactory disturbance and pain), 
neuropsychiatric disorders (including depression, anxiety, apathy, memory, language 
and executive function impairments as well as dementia) (Chaudhuri et al., 2006; 
Wolters et al., 2014). PD is a widespread disease with an age-dependent incidence of 
about 10-20 in 100.000 with a significant higher rate for men as for women. The 
average age of onset in PD is at about 60 years, although there are cases with early 
onset of the disease before 40 years (Wolters et al., 2014). 
PD was initially classified as a disease of the basal ganglia. The pathological hallmark 
of PD is the loss of dopaminergic neurones in the substantia nigra (Hughes et al., 
1992), resulting in the depletion of dopamine in the striatum (caudate and putamen) 
of the basal ganglia. However the disease is now recognized as a rather diffuse 
degeneration of the nervous system (Wolters et al., 2014) involving not only 
dopaminergic neurons in the pars compacta of the substantia nigra but also other 
neurons in the central and peripheral nervous system (including the autonomous 
and the enteric nervous system) (Klingelhoefer and Reichmann, 2015). PD is a 
synucleopathy, like dementia with Lewy bodies and multiple system atrophy, 
characterized by the presence of spindle- or thread-like Lewy neuritis in the cells, 
and of globular Lewy bodies in neuronal perikarya (body of neuron containing the 
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nucleus). Lewy neurites and Lewy bodies contain an aggregated form of the normally 
presynaptic protein a-synuclein and other components such as phosphorylated 
neurofilaments (component of neuronal cytoskeleton) and ubiquitin (heat shock 
protein required for the breakdown of abnormal proteins). As a consequence, loss of 
neurons is observed over time. Besides dopaminergic neurons, cholinergic, 
serotonergic and noradrenergic neurons are also affected in PD (Braak et al., 2003a; 
Wolters et al., 2014). Braak and colleges proposed that the disease results from an 
anatomically ascending degenerative process, starting in the brainstem (or even the 
enteric nervous system), with the earliest stage being the involvement of the motor 
part of the vagal nerve and the olfactory bulb (stages 1 and 2), spreading next to 
nuclei in the brainstem including the substantia nigra (pars compacta) (stages 3 and 
4) and affecting the neocortex in the last stages of the disease (stages 5 and 6). 
(Braak et al., 2003a)  The involvement of these areas could explain the non-motor 
symptoms of the disease. 
Particularly, in stages 1 and 2 the lesions are confined to the dorsal IX/X motor 
nucleus and/or the intermediate reticular zone. The caudal raphe nuclei (belonging 
to the midbrain reticular formation), the gigantocellular reticular nucleus and the 
coeruleus-subcoeruleus complex (nuclei complex in brainstem related with rapid eye 
movement (REM) sleep behaviour disorders (García-Lorenzo et al., 2013) are 
affected especially in stage 2. Olfactory structures, beginning from olfactory bulb and 
the olfactory nucleus, are also early in the pathological course of the disease 
affected. In stage 3 the pathology extents to the pars compacta of the substantia 
nigra. Other mesencephalic predilection sites, such as the pedunculopontine 
tegmental nucleus (component of the reticular activating system implicated in 
locomotion, cognitive functions and REM sleep (Mena-Segovia et al., 2004) and the 
magnocellular nuclei of the basal forebrain (including the basal nucleus of Meynert) 
start developing PD pathology.  In stage 4 the amygdala, the (ventral) claustrum, 
specific subnuclei of the thalamus are also affected. The pathological changes extend 
to other olfactory structures like the olfactory tubercle, the periamygdaloid and 
entorhinal cortex. In this stage the cortical involvement is only confined to the 
anteromedial temporal mesocortex. The last stages 5 and 6 are characterized from 
severe involvement of cortical areas, including insular areas, the anterior cingulate 
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cortex, prefrontal areas and finally the premotor and primary motor areas as well as 
sensory associating and primary sensory areas (Braak et al., 2003a). The motor 
symptoms of the disease appear, when the loss of dopaminergic neurons in the 
substantia nigra has surpassed the clinical threshold and this might be expected in 
stages 4 and/or 5 (Braak et al., 2003a; Wolters et al., 2014]. In the last stages (stage 
5 and 6) the damage in important limbic structures (amygdala, hippocampal 
formation, anteromedial temporal mesocortex) as well as extended neocortical 
territories can be associated with the increasing cognitive dysfunction. It must be 
however noted, that the severity of the pathology varies slightly from one person to 
another (Braak et al., 2003a). 
The exact cause of the disease remains unknown. Braak et al. hypothesized that PD 
might originate outside the nervous system, caused by an unidentified pathogen, 
passing the mucosal barrier of the gastrointestinal tract and secondarily reaching the 
central nervous system via retrograde axonal transport (via postganglionic enteric 
neurons entering the central nervous system along unmyelinated praeganglionic 
fibers generated from the visceromotor projection cells of the vagus nerve). By 
retrograde axonal and transneuronal transport such a causative pathogen could 
reach especially vulnerable subcortical nuclei and in this way gain access to the 
cerebral cortex (Braak et al., 2003b). The same study group proposed the dual-hit 
hypothesis with pathogenic access to the brain through the stomach and nose 
(Hawkes et al., 2007).  
As Braak’s model does not explain the synchronicity of many of PD symptoms, Braak 
and his colleges suggested the cortico-basal ganglia-cortical circuit (Braak and Del 
Tredici, 2008). Indeed, a wide range of experimental evidence supports the concept 
of cortical-basal ganglia-thalamic-cortical closed loops, in which the basal ganglia 
participate in various functional loops (Alexander et al., 1986; Parent and Hazrati, 
1995; Mc Haffie et al., 2005). The cortico-basal ganglia parallel circuits´ model 
consists of motor, associative and limbic loops (Fig. 1) (Obeso et al., 2009; Juri et al., 
2010). Each loop has its origin in different cortical areas serving specific functions 
(Romanelli et al., 2005), but interaction has also been shown to exist between the 
circuits (Joel and Weiner, 1997; Obeso et al., 2000). The motor striatum (dorsolateral 
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putamen and dorsolateral region of the caudate) is innervated by the primary and 
supplementary motor cortex. The associative striatum (consisting of the largest part 
of the nucleus caudatus and of the putamen) receives input from associative areas of 
the cortex, mainly from the prefrontal cortex. The limbic striatum (nucleus 
accumbens and the ventral parts of the putamen and nucleus caudatus (Robbins and 
Evritt, 1996)) receives input from limbic structures: the hippocampus, the amygdala, 
orbitofrontal, infralimbic and prelimbic cortices. This arrangement forms the 
neuronal basis for the influence of the basal ganglia on sensomotor, cognitive and 
executive behavioural and emotional-motivational functions.  
 
 
 
Fig. 1 The cortico-basal ganglia loops 
 
In the current “general” view of the basal ganglia, the striatum and subthalamic 
nucleus are the two main accesses from the cortex (Juri et al., 2010) and the globus 
pallidus internus is the efferent point via the thalamus to the cortex. In addition, via 
thalamus a phylogenetically older system of projection ascending from brainstem 
structures like the superior coliculus and pedunculopontine nucleus provides the 
basal ganglia with relative unprocessed external (visual, auditory, somatosensory, 
etc.) and internal (viscerosensory, homeostatic, etc.) information. The output of the 
basal ganglia has an ascending and a descending component. The extensive 
ascending component reaches via medial and ventral thalamic nuclei, to the 
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premotor and prefrontal areas cortical areas in the frontal lobe, thus closing the so-
called basal ganglia-thalamocortical circuits. The descending component consists of 
basal ganglia projections directed to mesencephalic structures that, in turn, give rise 
to fibers that descend further to motor output structures in the lower brainstem and 
spinal cord, as well as to fibers that ascend to forebrain structures. These projections 
form the neuronal basis for the influence of the basal ganglia on posture and balance 
as well as on muscle tone (Braak and Del Tredici, 2008; Groenewegen et al., 2014; 
McHaffie et al., 2005). Across this wide array of motor and behavioural functions in 
which the basal ganglia are involved, the mechanism by which the basal ganglia 
contribute to these functions is though selecting appropriate responses in a 
particular context and, at the same time, though suppressing inadequate responses 
(ˮresponse selectionʺ) (Wolters et al., 2014). Thus, the basal ganglia can be 
considerated as a subcortical ʺcontrol deskˮ, responsible for choosing the best action 
modus among different action patterns (Diederich and Parent, 2012).  
 
1.2 Non-motor symptoms of Parkinson’s disease 
Olfactory dysfunction in Parkinson’s disease   
The olfactory dysfunction in PD includes impairment of odor detection (the 
threshold or the perception of odors at low concentrations), identification (the 
ability to name an odor) and discrimination (distinction of different smells) (Doty et 
al., 1988; Mesholam et al., 1998). Olfaction is impaired in 70-90% of patients with 
(sporadic) PD and occurs early in the course of the disease (Doty et al., 1988). 
Hyposmia has even been shown to exist in potential premotor stages of PD, i.e. REM 
sleep behavior disorder (Stiasny-Kolster et al., 2005). Prospective studies have 
indeed established hyposmia as a pre-motor sign of PD that can precede the onset of 
the motor symptoms by as long as 5 years (Ponsen et al., 2004; Ross et al. 2008). This 
olfactory dysfunction seems to be unrelated to gender, disease duration and 
severity, dopaminergic therapy (Doty et al., 1988; Hawkes et al., 1997) as well as 
cognition (Doty et al., 1989). Most PD patients are unaware of their olfactory deficit 
until testing (Doty, 2007). Degeneration of anatomical areas involved in olfaction is 
responsible for the olfactory dysfunction in PD. Such neuropathologic changes are 
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found in the olfactory bulb and the anterior olfactory nucleus in the early disease 
stages while changes in the olfactory cortex (perirhinal cortex) and in limbic 
structures like amygdala are found in more advanced stages (Braak et al., 2003; 
Benarroch, 2010). 
 
REM sleep behavior disorder in Parkinson’s disease 
REM sleep behavior disorder (RBD) is a parasomnia characterized by the lack of 
motor inhibition during REM sleep, leading to loss of the normal skeletal muscle 
REM-related atonia thus enabling patients to physically enact their dreams, which 
can often be vivid or unpleasant and can lead to a vigorous, potential harmful 
(dream-enacting) behavior (Wolters et al., 2014). Vocalisations (talking, shouting, 
vocal threats) and abnormal movements (arm or leg jerks, falling out of bed, violent 
movements) are commonly reported by bed partners. Surprisingly, there can be 
restoration of normal motor activity, with disappearance of parkinsonian features 
during RBD. RBD is a potential marker of neurodegenerative disease particularly PD 
and Lewy body dementia (Cochen De Cock, 2013). RBD is present in up to 60% of 
patients with PD and it can appear before, at the same time or after the onset of PD. 
RBD can precede the development of the motor signs of Parkinson’s disease even 15 
years before (Cochen De Cock, 2013) and longitudinal data suggest that RBD 
pronounces the onset of motor symptoms in up to 40% of patients (Chaudhuri et al., 
2006) The sublaterodorsal nucleus, the precoeruleus complex and the magnocellular 
reticular formation in the brainstem have been implicated in the pathophysiology of 
RBD (Chauduri et al., 2006; Boeve et al., 2007; Postuma et al., 2012). 
 
Dysautonomia in Parkinson’s disease 
Dysautonomia in PD includes orthostatic hypotension, constipation and urogenical 
dysfunction (Poewe, 2008). Orthostatic hypotension and urogenical dysfunction are 
rather late features in PD (unlike Multiple System Atrophy) (Poewe, 2008). The 
pathophysiology of autonomic disorders in PD involves degeneration and 
dysfunction of the medullary nuclei as well as of the peripheral nervous system 
(myenteric plexus) (Chauduri et al., 2006; Poewe, 2008).  
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Cognitive impairment, depression and apathy in Parkinson’s disease 
 The prevalence of cognitive deficits in PD ranges from 19-36% of patients 
(Goldmann and Postuma, 2014). Cognitive impairment in PD is typically a 
dysexecutive syndrome, with impairment of attention and ability to plan, problem-
solving and regulating goal-directed behavior (Emre, 2003). Language deficits are 
also described in PD, such as impaired verbal fluency and naming difficulty 
(Muzerengi et al., 2007), as well as visuospatial deficits and to an extend impairment 
of learning and memory (Dubois and Pillon, 1997). Minor cognitive deficits may be 
present at the early stages of the disease while a dysexecutive syndrome is frequent 
as the disease progresses. However, executive function impairments are commonly 
noted even in PD patients, who do not have dementia (Zgaljardic et al., 2003). 
Regarding the pathology of cognitive impairment in PD, the presence of cortical and 
subcortical Lewy bodies, amyloid deposition (Alzheimer-type pathological changes) 
as well as pathology in monoaminergic and cholinergic nuclei (that project to the 
cortex) is implicated (Aarsland et al., 2005; Emre et al., 2007). 
Depression is common in PD patients: a clinically significant depression is present in 
approximately 30–50% of PD patients (Poewe and Seppi, 2001; Lemke, 2008; 
Barone, 2011). The prevalence rates in studies vary from 2.7% to 55.6% for major 
depression, 13% to 34.5% for minor depression and 2.2% to 31.3% for dysrhythmia 
(Grover et al., 2015). Mechanisms underlying depression are related to disturbances 
of noradrenalin, serotonin and dopamin transmissions in limbic and cortical 
structures. The noradrenalin locus coeruleus and serotonin raphe neurons 
degenerate over the course of PD, which leads to decreases in serotonin and 
noradrenalin levels in regions innervated by these structures (Ossowska  and Lorenc-
Koci, 2013).  
Apathy, which is described as flattening of affect, decreased motivation or lack of 
initiative, is a common finding in patients with PD.  Patients show reduced interest 
and participation in the main activities of daily living and a trend towards early 
withdrawal from initiated activities. Apathy in PD patients has a prevalence that 
varies from 16.5% to 42%, depending on the assessment tools and the patients´ 
characteristics (Dujardin et al., 2007). Apathy symptoms could be due to neuronal 
degeneration in areas that mediate goal-directed behavior (Brown and Pluck, 2000) 
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such as frontal-subcortical areas or reward centres such as dopamine projections 
between the ventral tegmentum and nucleus accumbers (Chaudhuri et al., 2006) or 
again mesolimbic dopaminergic denervation and thus dysfunction of the limbic 
system (Dujardin and Lopes, 2014).  
 
1.3 Facial emotion recognition in Parkinson’s disease  
Among the spectrum of non-motor, in particular neuropsychological symptoms in 
PD, the ability of patients to recognize emotions in others’ facial expressions, a skill 
of great importance for non-verbal communication and social interaction, is gaining 
growing interest. Facial emotion recognition (FER) is described in several studies to 
be impaired in PD patients. The studies focused on some or all six basic emotions i.e 
happiness, fear, anger, sadness, disgust and surprise. 
1.3.1 Previous studies of facial emotion recognition in Parkinson’s disease  
A number of studies assessed facial emotion recognition in PD patients with 
inconsistent findings. The first study, which suggested that emotional processing of 
facial stimuli is selectively impaired in PD patients, was the study of Blonder et al. 
(Blonder et al., 1989). In this study, patients showed impairment of emotional 
processing of facial stimuli compared to healthy controls but there was no 
differences found between patients with right hemiparkinsonism and those with left 
hemiparkinsonism in the pattern of deficits exhibited. Beatty et al. (Beatty et al., 
1989), who compared two groups of PD and of chronic progressive multiple sclerosis 
patients with two groups of neurologically normal controls respectively, found that 
(both) PD (and multiple sclerosis) patients were less accurate in judging emotional 
expressions conveyed by the photographs depicting fundamental affective states 
and were equally impaired in judging each of the seven emotional states (happy, sad, 
angry, afraid, disgusted, surprised or neutral). Moreover, they showed no particular 
tendency to confuse faces expressing emotions of opposite polarity (e.g happy and 
sad). Borod et al. (Borod et al., 1990) examined emotional processing (perception 
and expression) using a both facial and vocal channel, in various neurological and 
psychiatric group of patients (schizophrenic, depressive, right-brain damaged, PD) 
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and normal control right-handed adults. Regarding perception of facial stimuli, PD 
patients were significantly less accurate than normal controls. PD patients identified 
more accurately positive faces (than neutral and negative ones), whereas normal 
controls identified more accurately neutral faces. Negative emotions were identified 
with the least accuracy in both the PD and normal control group. Jacobs et al. 
(Jacobs et al., 1995), using perceptual and imagery tasks, found that PD patients 
were impaired on two tasks of facial affect perception: the emotional facial 
characteristics, at which the patient answers questions on an exhibited face, and the 
affect discrimination task of the Florida Affect Battery-revised test, at which subjects 
were asked whether two faces displayed the same or a different emotion. On the 
emotional facial characteristics test, fear and sadness showed the greatest 
differences between the two groups with less accuracy in the PD group among the 
emotions tested (happiness, sadness, anger, and fear). However, on an affect 
matching task, at which subjects were required to match a target emotional face 
with one of five face alternatives that displayed the same or a similar facial emotion, 
there was no difference found between the PD patients and normal control subjects. 
Breitenstein et al. (Breitenstein et al., 1998), using both facial and auditory stimuli, 
comparing patients with focal cortical lesions and PD patients with two matched 
control groups, revealed significant differences in recognizing facial expressions 
between PD patients with bilateral symptoms compared to healthy controls. With 
respect to single emotions, a differential deficit pattern was only observed for the 
affective prosody subtests and not for the facial expressions subtests.  
Moreover, the study by Kan et al. (Kan et al., 2002) showed a significant impairment 
in the recognition of fear and disgust in PD patients from moving (videotaped) facial 
stimuli (but not from prosodic or written verbal stimuli). Yip et. al (Yip et. al, 2003) 
showed an impairment in the recognition of all emotions in patients with bilateral 
motor symptoms compared to healthy controls, with the recognition of fear and 
sadness being more impaired, while the right-sided PD patients showed an 
impairment in the recognition of all emotions except happiness, especially in the 
recognition of sadness and disgust. Sprengelmeyer et al. (Sprengelmeyer et al., 
2003), who examined the issue in unmedicated (early stage) PD patients and 
medicated (with more advanced disease), showed that  unmedicated PD patients 
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performed significantly worse than controls in recognizing fear, sadness, anger and 
disgust, while the medicated PD patients performed significantly below controls in 
recognizing fear and anger. Notably, the unmedicated group showed a consistently 
worse performance in recognition of disgust compared with the medicated group. 
Dujardin et al. (Dujardin et al., 2004a) reported an impairment of anger, disgust and 
sadness in early unmedicated PD patients independent of the intensity of emotional 
facial expressions exhibited, although the same authors showed no impairment in 
the facial emotion recognition in 12 PD patients in the pre-operative phase of deep 
brain stimulation in another study (Dujardin et al., 2004b).  
Furthermore, Suzuki et al. (Suzuki et al., 2006) showed a selective deficit in the 
recognition of disgust in early PD patients with a refined method using morphed 
visual stimuli, which was not present when using the conventional method of 
assessing FER. A french study from Lachenal-Chevallet et al. (Lachenal-Chevallet et 
al., 2006) showed a deficit for fear and disgust recognition in a small sample of 
participants. Lawrence et al. (Lawrence et al., 2007) showed impairment in the 
recognition of anger in a group of PD patients transiently withdrawn from dopamine 
replacement therapy. Arriati et al. (Arriati et al., 2008) using a facial emotion and 
emotional prosody recognition battery showed a deficit in recognizing fear and 
sadness from facial stimuli in PD patients. Clark et al. (Clark et al., 2008) showed 
impairment in the recognition of anger and surprise in PD. Moreover, the 
recognition of anger was shown to be impaired in patients with right hemisphere 
pathology (left body side onset of motor symptoms) and surprise by those with left 
hemisphere pathology (right body side of onset). At the same study male PD patients 
exhibited deficits in the recognition of fear (Clark et al., 2008). The results were 
replicated in a study of the same authors (Clark et al., 2010), which included a sub-
sample of the original cohort and primarily showed that PD patients have subtle 
differences in scanning behaviors during viewing tasks of emotion categorization 
compared with healthy control subjects, which are driven by different perceptual 
processes and cognitive strategies. PD patients obtained lower scores compared to 
healthy controls in all emotions except happiness in the study of Ibarretxe-Bilbao et 
al. (Ibarretxe-Bilbao et al., 2009), which used high resolution structural magnetic 
resonance images (MRI) to test whether there are any structural changes that could 
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explain the impairment of recognition of facial emotions and decision-making in 
early PD. Assogna et al. (Assogna et al., 2010) using high- and low-intensity stimuli, 
comprising of digitized pictures of three-dimensional models of faces depicting facial 
expressions of evoked or felt emotions, showed that PD patients recognized fewer 
low- and high-intensity facial expressions of disgust than healthy controls. Paulmann 
and Pell (Paulmann and Pell, 2010) found a significant difference between two small 
groups of PD and healthy participants in identifying emotions from dynamic facial 
stimuli, although not from static ones. Herrera et al. (Herrera et al., 2011) showed an 
emotion recognition deficit in PD patients in absence of other cognitive deficits that 
could explain it. Narme et al. (Narme et al., 2011) in a study assessing facial emotion 
recognition and facial configural processing (processing of the spatial relations 
between facial features) as well, showed a deficit of the PD group in recognizing 
anger and fear compared to the control group. A study from the same author 
(Narme et al., 2013), which investigated emotional and cognitive social processes in 
relation to behavioral disorders, showed also impaired facial emotion recognition of 
fear and sadness in PD. Baggio et al. (Baggio et al., 2012) in a neuroimaging study 
showed a significant worse performance of the PD group compared to the healthy 
control group.  
Buxton et al. (Buxton et al., 2013), who investigated the issue using subtle 
expressions of emotion, showed that although PD patients identified emotional 
expressions on phototypical test (Ekman and Friesen, 1976) as accurately as the 
control group, as the facial expressions of emotion became more subtle, the PD 
group was significantly less accurate at identifying disgust in the moderate level, 
sadness at the most difficult level and happiness at both levels of subtlety. Saenz et 
al. (Saenz et al., 2013), showed a significantly impaired recognition of fear and 
sadness from facial stimuli (hybrid faces derived from one female face) in the PD 
group. Hipp et al. (Hipp et al., 2014), found that patients with early PD performed 
worse on almost all lower order vision test (including contrast sensitivity and color 
discrimination) and on the recognition of higher vision performance i.e recognition 
of sadness compared to healthy controls. Alonso-Recio et al. (Alonso-Recio et al., 
2014a) using facial expression (including all basic emotions except of surprise) and 
facial identity characteristics (age and gender) discrimination and identification tasks 
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found significant differences only in the facial expression identification task between 
PD and healthy controls. Marneweck et al. (Marneweck et al., 2014a) found 
impairments in discriminating emotional expressions of graded intensity from 
neutral expressions and four of the basic emotions (anger, disgust, happiness and 
sadness) in PD patients.  An overview of the results of the most important studies 
accessing FER in PD patients can be seen in Table 1.  
 
On the contrary, twelve studies (Caekebeke et al., 1991; Dewick et al., 1991; 
Madeley et al., 1995; Adolphs et al., 1998; Tessitore et al., 2002; Pell and Leonard, 
2005; Biseul et al., 2005; Yoshimura et al., 2005; Cohen et al., 2010; Pèron et al., 
2010; Ventura et al., 2012; Wieser et al. 2012) failed to identify any facial emotion 
recognition impairment between PD patients and the healthy group of participants. 
Caekebeke et al. (Caekebeke et al., 1991), who examined the issue using cartoons 
showing faces that depicted an emotional state in a PD group withdrawn from the 
Parkinson replacement treatment the night before the assessment and a control 
group of subjects found no significant difference between the two groups. Dewick et 
al. (Dewick et al., 1991) showed no significant difference between groups either for 
the total score or for the three individual expressions (happy, angry, and sad). 
Madeley et al. (Madeley et al., 1995), using as stimuli the photographs taken from a 
small sample of participants themselves (PD and healthy controls), found that the 
two groups did not differ in their ability to recognize facial expressions or in the 
pattern of misidentification errors. Adolphs et al. (Adolphs et al., 1998) found an 
intact recognition of emotions in a quantitative task (rating of emotions). Tessitore 
et al. (Tessitore et al., 2002) using functional magnetic resonance imaging studied 
the response of patients during a hypodopaminergic state (i.e ≥12 hr after their last 
dose of dopaminergic treatment) and again during a dopamine-replete state to 
fearful and angry facial stimuli, found that although the mean accuracy score was 
lower during the drug-off state compared with both the drug-on state and normal 
control subjects, this difference did not reach statistical significance. Furthermore, 
Yoshimura et al. (Yoshimura et al., 2005) in a study using visual event-related 
potentials in response to the viewing of fearful facial expressions in a small sample of 
patients and controls, found no difference in the task performance. Pell and Leonard 
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(Pell and Leonard, 2005), using discrimination, identification and rating tasks of five 
basic emotions (fear excluded) failed to show a significant difference in the 
performance of PD and controls. Furthermore, Cohen et al. (Cohen et al., 2010) 
showed no deficit of PD patients in encoding facial emotion and object information, 
although PD patients performed significantly slower than controls in a test requiring 
high cognitive load, especially working memory (N-back task). Ventura et al. (Ventura 
et al., 2012) found no difference in both correct responses and reaction time among 
PD and healthy control groups on identification and discrimination facial tasks. 
Wieser et al. (Wieser et al., 2012), showed reduced early visual emotion 
discrimination in PD patients based on visual event-related potentials, although PD 
patients showed no impairment in emotion recognition (measured by affective 
ratings).   
 
A recent meta-analysis conducted by Gray and Tickle-Degnen (Gray and Tickle-
Degnen, 2010) examined the influence of six potential moderators (stimulus 
modality, task type, emotion displayed, medication status, depression status, 
executive function and visuospatial ability) on emotion recognition from facial and 
prosodic stimuli in PD. Regarding stimulus modality, the meta-analysis showed a 
deficit in emotion recognition in PD from both faces and voices, showing a greater 
deficit (effect size) for the recognition of emotion from prosody. Concerning task 
type, the meta-analysis showed deficits in both discrimination (deciding which of 
two photographs matches an expression or deciding whether two pictures pictured 
the same emotion) and identification (using labeling of an emotion) tasks, while 
discrimination tasks yielded a significantly greater deficit. The smaller deficits were 
found in rating tasks (i.e rating the extent of the emotion of a face showed) and can 
be attributed, according to the writers, to the very small number of studies using this 
kind of tasks and it is unlikely that they exhibit real deficits. Regarding specific 
emotion recognition deficit, PD patients were more impaired in recognizing negative 
emotions (anger, disgust, fear and sadness) than positive emotions (happiness, 
surprise). Concerning medication status, although there was a greater impairment 
(larger effect size) found among patients in hypodopaminergic state at the time of 
the testing, this finding was not significant.  Moreover, the meta-analysis showed 
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that the emotion recognition deficit in PD exists independent of patients´ depression 
status. Regarding visuospatial ability, the results suggested that the facial emotion 
recognition deficit in PD exists beyond a deficit in face processing, while concerning 
the executive functions the results were less clear showing a difference favoring the 
control group.  
23 
 
 
Table 1. Overview of the most important studies accessing FER in PD patients 
Study Test used Emotions tested Participants FER deficits PD Remarks 
Yip et al., 2003 Matsumoto and Ekman 
(Identification and 
discrimination task) 
all (six basic 
emotions) 
64 PD (56 
bilateral PD, 8 
right-sided) 
64 HC 
 bilateral PD: total 
score, fear, sadness 
 Right-sided PD: 
total, all except 
happiness 
 
Sprengelmeyer et al., 
2003 
Ekman 60 Faces Test and 
Emotion Hexagon 
all 20 medicated PD 
6 unmedicated PD 
40 HC 
 PD vs HC: total 
 unmedicated vs  
medicated PD: 
disgust (worse the 
unmedicated) 
Computer manipulated 
pictures in the Emotion 
Hexagon task 
Dujardin et al., 2004 Hess and Blairy Series 
(from Matsumoto and 
Ekman) 
anger, disgust, 
sadness 
18 PD 
18 HC 
total score PD have not yet received 
treatment 
Suzuki et al., 2006 Matsumoto and Ekman all 14 PD 
39 HC 
total score and disgust ONLY 
in the refined method  
 MMSE 24-30 
 Conventional and 
refined method of 
FER test used 
 Early PD patients 
Lawrence et al., 2007 Ekman 60 Faces Test all 17 PD 
21 HC 
anger PD off-medication 
Ariatti et al., 2008 Facial emotion 
recognition battery (faces 
from Ekman and Friesen) 
all except 
surprise 
27 PD 
68 HC 
In the Facial affect naming  
and Facial affect matching 
subtests: total  score, fear, 
sadness 
MMSE≥23 
Clark et al., 2008 cropped Photos from 
Ekman and Friesen 
all 20 PD 
23 HC 
total  score, anger, surprise  
Ibarretxe-Bilbao et al., 
2009 
Ekman 60 Faces Test all 24 PD 
24 HC 
total score  Early PD 
 Primary 
neuroimaging 
study 
 
Assogna et al., 2010 Penn Emotion Recognition 
Test 
all except 
surprise 
70 PD 
70 HC 
disgust MMSE>24 
Herrera et al., 2011 Mc Brain Face Stimulus 
Set 
all 40 PD 
19 HC 
total score MMSE>25 
Narme et al., 2011 Photos from Ekman and 
Friesen Series 
happiness, fear, 
disgust, anger 
10 PD 
10 HC 
total  score, anger (in the 
upright task) 
Upright, upside-down, 
configural task 
Baggio et al.,  2012 Ekman 60 Faces Test all 39 PD 
23 HC 
total score, fear, anger, 
sadness, disgust 
Primary neuroimaging study 
Buxton et al.,  2013 Ekman and Friesen all 30 PD 
30 HC 
 no difference at 
the easy level  
 Significant 
differences for 
specific emotions 
at moderate and 
difficult level 
Easy (prototypical), moderate 
and difficult level of task 
Saenz et al., 2013 Adapted from pictures of 
facial Affects 
fear, happiness, 
sadness 
24 PD 
24 HC 
 fear, sadness 
 no significant 
difference between 
low and high levels 
of intensity in PD 
 Stimuli with 
increasing level of 
intensity by 10% 
 PD duration<4 
years 
Hipp et al.,  2014 Ekman 60 Faces Test all 28 PD 
25 HC 
sadness  Early PD patients 
(≤3 years disease 
duration) 
 MMSE 25-30 (PD 
sign. diff.  with HC) 
Alonco-Recio et al.,  
2014a 
80 cropped photos from 
FACES Database (Ebner, 
Riediger, & Linderberger, 
2010) 
(Identification and 
discrimination task) 
all except for 
surprise 
53 PD 
53 HC 
total score  
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1.3.2 Neuroanatomy linked with facial emotion recognition 
Several brain structures have been reported to be involved in the identification of 
facial expressions. A lot of information to this issue is provided from lesional studies. 
Blonder et al. (Blonder et al., 1989) suggested bilateral involvement in emotional 
processing at the subcortical level and Jacobs et al. (Jacobs et al., 1995) proposed 
that the basal ganglia, together with the right hemisphere, are part of a neural 
network serving emotional facial tasks (perceiving emotional faces, emotional facial 
imagery). A lateralization of the recognition of negative facial emotions involving 
discrete visual and somatosensory cortical areas in the right hemisphere has been 
reported (Adolphs et al., 1996) in patients with focal cortical lesions.  
Neuroimaging studies have also examined the issue of neural substrates of facial 
emotion recognition. Spengelmeyer et al. (Spengelmeyer et al., 1998) showed 
enhanced activity by fMRI in healthy volunteers in the right putamen and the left 
insula cortex in response to disgusted facial expressions, whereas enhanced activity 
in the posterior part of the right gyrus cinguli and the medial temporal gyrus of the 
left hemisphere was observed during processing of angry faces. Fearful expressions 
activated the right fusiform gyrus and the left dorsolateral frontal cortex. For all 
three emotions investigated, activation of the inferior part of the left frontal cortex 
(Broadmann area 47) was found in common. Phillips et al. (Phillips et al., 1998) 
showed that fearfull stimuli activated the amygdala while facial expressions of 
disgust activated the anterior insula and the caudate-putamen. A recent meta-
analysis of fMRI studies of Fusar-Poli et al. found that processing of emotional faces 
was associated with increased activation in a number of visual areas (fusiform gyrus, 
inferior and middle occipital occipital gyri, lingual gyrus), limbic areas (amygdala and 
parahippocampal gyrus, posterior cingulate), temporal areas (middle/superior 
temporal gyrus), temporoparietal areas (parietal lobule, middle temporal gyrus, 
insula), prefrontal areas (medial frontal gyrus), subcortical areas (putamen) and the 
cerebellum (declive). Regarding processing of different emotions, happy, fearful and 
sad faces activated the amygdala, with greater amygdala sensitivity for fearful faces, 
while disgusted and angry faces activated the insula with greater insular sensitivity 
for disgusted faces. Furthermore there was a thalamic activation shown in response 
25 
 
to disgusted faces, indicating that the insular-thalamic pathway may represent a core 
role in recognizing of disgust, probably as part of a neural network. On the other 
hand, neural response in the visual cortex and cerebellum was observed in all 
emotions. It is possible, that the visual areas are involved in early perceptual 
processing of facial stimuli, which may be independent of emotional valence 
(Adolphs, 2002b). The medial frontal cortex, which participates in the conscious 
experience of emotion, inhibition of excessive emotion or decision-making by 
observing one’s own emotional state, seems to be activated by fearful faces, 
whereas happy faces activated the anterior cingulate cortex, which is involved in the 
response to an emotive visual stimulus. Finally, the cerebellum showed no 
differentiation in brain activation across emotions. The cerebellum is connected with 
the reticular system, cortical association areas and limbic structures such as the 
amygdala, the hippocampus and the septal nuclei (Baillieux et al., 2008; Fusal-Poli et 
al., 2009), providing an explanation for the activation pattern found in the 
metaanalysis.  
Two neuroimaging studies have also examined the issue of neural substrates of FER 
in PD. In the study of Ibarretxe-Bilbao et al. (Ibarretxe-Bilbao et al., 2009), PD 
patients, who obtained lower scores in the recognition of all emotions except 
happiness, had significant volume loss in the right amygdala and bilateral 
orbitofrontal cortex in comparison with healthy controls. Gray matter volume of the 
bilateral orbitofrontal cortex was also found to correlate positively with overall 
emotion recognition in PD patients in this study. Baggio et al. (Baggio et al., 2012) 
using based morphometry analysis, revealed areas of positive correlation between 
individual emotion recognition and gray matter volume in PD patients: in the right 
orbitofrontal cortex, amygdala and postcentral gyrus and sadness identification; in 
the right occipital fusiform gyrus, ventral striatum and subgenual cortex and anger 
identification, and in the anterior cingulate cortex and disgust identification. White 
matter analysis in the same study, revealed significant positive correlations between 
the frontal portion of the right inferior fronto-occipital fasciculus and the 
identification of sadness. 
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Summarizing, a large number of different structures participate in recognizing 
emotions in faces including the orbitofrontal cortex, the anterior cingulate cortex, 
the amygdala, the basal ganglia, the right parietal cortex and visual processing areas 
like the occcipito-temporal cortex (Adolphs, 2002a; Adolphs, 2002b). Adolphs 
mentioned that these structures participate in multiple processes and at various 
points in time, thus making it difficult to assign this complex function to a single 
structure (Adolphs, 2002b). Moreover, possible neural substrates, responsible for 
the facial recognition involve the basal ganglia limbic loop, in which the ventral 
striatum receives projections from the orbitofrontal cortex, anterior cingulate, 
entorhinal cortex, amygdala and hippocampus and in turn projects to the ventral 
pallidum and the latter to the thalamus and amygdala (Alexander and Crutcher, 
1990; Alexander et al., 1990; Clark et al., 2008). 
Particularly relevant for PD, regarding specific emotions, are the associations 
between anger and dopaminergic striatal system, in particular the ventral striatum 
(Calder et al., 2004; Lawrence et al., 2007), disgust and the basal ganglia and insula 
(Phillips et al., 1997; Sprengelmeyer et al., 1998; Calder et al., 2000; Suzuki et al., 
2006), fear and the amygdala (Adolphs et al., 1994; Adolphs et al., 1999; Calder et 
al., 1996; Vytal and Hamann, 2010; Tessitore et al., 2002; Sato et al., 2002; 
Yoshimura et al., 2005; Kawamura et al., 2009) and happiness and the ventral 
striatum and putamen (Phan et al., 2002), as all these areas are affected from PD 
pathology (Braak et al., 2003). 
 
1.4 Aim of the study 
As mentioned above, the results of studies assessing facial emotion 
recognition in PD patients are inconsistent. The aim of the study was to further 
investigate whether facial emotion recognition is (significantly) impaired in PD 
patients compared with healthy controls and whether there is a specific emotion 
recognition deficit regarding the six basic emotions (happiness, anger, sadness, fear, 
disgust and surprise). Furthermore, possible associations of facial emotion 
recognition with demographic (such as age, sex, handedness, education, Parkinson 
medication) and clinical parameters i.e motor (disease duration, age of onset, 
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severity of motor impairment, type of PD, more affected side, hypomimia, freezing 
of gait, postural instability) and non-motor symptoms (presence of REM sleep 
behavior disorder, autonomic dysfunction) were examined. Among the most 
prominent non-motor features of PD is olfactory impairment, which as mentioned 
occurs in at least 90% of patients and often appears in the pre-motor stage of the 
disease (Doty, 2012). Facial emotion recognition and olfaction share common 
neuroanatomical substrates such as the amygdala and the orbitofrontal cortex (Doty, 
2012; Soudry et al., 2011). Furthermore, the perception of facial expressions may 
integrate cues from sensory modalities other than vision, including olfaction (Leleu, 
2015). Thus, particular interest was taken in examining whether poorer performance 
in facial emotion recognition is associated with impaired olfaction, as this 
relationship in PD has not yet been directly investigated. As FER requires the 
integrity of cognitive functions such as visuospatial abilities, attention, language and 
executive functions (Assogna et al., 2010) and may as well be influenced by mood 
disorders (Leppanen, 2006, Martinez-Corral et al., 2010), the association of FER in PD 
with cognitive status, depression and apathy measures was also examined. 
 2.    Patients and Methods 
2.1 Participants 
Thirty-four patients with PD (18 men, 16 women) and 24 age- and sex-matched 
healthy controls (HC) (14 men, 10 women) were enrolled in this study. The study was 
approved by the ethic committee of the medical council of Saarland and all the 
participants gave their informed written consent to participate (Votum number 
98/14). The diagnosis was made according to the United Kingdom PD Society Brain 
Bank Criteria (Hughes et al., 1992). PD patients were recruited from the department 
of neurology of the university hospital of Saarland, Germany. HC were recruited from 
the community (usually spouses of the patients). The groups did not differ with 
respect to age, sex, mini mental state examination score (U=362, p=0.437>0.05) and 
education (U=402, p=0.924>0.05). The groups differed in the depression score (BDI) 
with PD patients having a higher depression score (U=231, p=0.005<0.05).  
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Exclusion criteria for all subjects were: history of other neurological or psychiatric 
illness (other than PD in the PD group), history of structural brain lesion (e.g. history 
of stroke, encephalitis, severe head injury or head surgery), dementia (defined as 
Mini mental status score <27), delirium, acute confusion state or (dopamine-
induced) psychosis or hallucinations, use of CNS-active medications (e.g. treatment 
with neuroleptics), except for use of dopaminergic, antidepressants and anxiolytics 
in the PD group, severe depression (Beck Depression score>17), history of drug or 
alcohol addiction, history of eye disease resulting in uncorrected abnormal vision, 
history of olfactory deficits resulting in a decrease of odor (e.g. acute upper 
respiratory tract infection, nose surgery, chronic sinusitis, chronic exposure to 
substances like pesticides, metallic dusts, industrial solvents or thinners, cleaning 
products). An additional exclusion criterion in the HC group was a family history of 
PD or other neurodegenerative diseases. All participants were native German 
speakers. One control subject had a light diabetic polyneuropathy. Another control 
subject had a possible seasonal allergic rhinitis (not at the time of the testing). 
Moreover one PD patient had a nose surgery with probable reduced odor after 
surgery; the results concerning olfactory function testing were also calculated when 
these two subjects were excluded.  
The PD group had the following demographic characteristics: a mean age of 68.3 
years (± 8.2) with a range of 53-80 years, a median education of 13 years with a 
range of 9-20 years. The median Mini–Mental State Examination (MMSE) was 29 
with a range of 27-30 and the Beck Depression Inventory (BDI) score was 8 with a 
range of 0-17. Thirty one patients were right-handed (91.2%) and 3 (8.8%) were left-
handed. Regarding the disease characteristics the median age at onset of PD 
(defined as onset of symptoms) was 60 with a range of 35-75 years; the median 
disease duration was 9 with a range of 2-20 years. Sixteen patients (47.1%) had an 
akinetic-rigid, 13 (38.2%) an equivalent and 5 (14.7%) a tremor-dominant PD type. 
The predominant side of motor symptoms was in 20 patients (58.8%) the right side 
and in 14 (41.2%) the left side. The mean Unified Parkinson's Disease Rating Scale 
(UPDRS) total score was 38.8 (±13) with a range of 15-67 and the mean UPDRS III 
score was 20.7 (± 6.7) with a range of 6-36. The modified Hoehn and Yahr (H&Y) 
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score, as measure of disease disability, had a median (=mean) of 2.5 and a range of 
1-4. The modified Schwab und england activities of daily living scale was in 9 patients 
(26.5%) 100%, in 10 patients (29.4%) 90%, in 7 patients (20.6%) 80%, in 6 patients 
(17.6%) 70%, in one patient (2.9%) 60% and in another one (2.9%) 50%. Sixteen 
patients (47.1%) reported orthostatic dysregulation i.e one or more of the following 
symptoms: orthostatic hypotonia, urinary bladder disorder (urinary urgency), 
obstipation. All patients were taking medication for treatment of PD with a median 
daily L-Dopa equivalent dosis (LEDD) of 577 with a range of 100-2417.5 mg, 
calculated as suggested by Tomlinson et al. (Tomlinson et al., 2010) (median daily 
dosis of L-dopa 275 mg, range 0-1050.8 mg). The patients received most frequently 
L-Dopa and benzerazide combinations or L-Dopa, Carbidopa und entacapone 
combinations, dopamine agonists (most commonly pramipexole, rotigotine and 
ropinirole), inhibitors of monoamine oxidase like rasagiline and amantadine. Less 
commonly taken were anticholinergica like trihexyphenidyl (3 patients) and 
bornaprine (1 patient), antidepressants or anxolytics like mirtazapine (3 patients) 
and citalopram (2 patients) as well as hypnotic agents like oxazepam (1 patient) and 
zopiclone (2 patients). All patients were tested during ʺonˮ state i.e while being 
administered their anti-parkinsonian medications. Regarding smoking habits one 
patient (2.9%) was smoker, 21 patients (61.8%) non-smokers and 12 (35.3%) ex-
smokers. The mean pack-year number was 5.24 (±10.7) with a range of 0-49 years.  
The HC group had a mean age of 69.5 (±8) years with a range of 53-83 years and a 
median education of 13 years with a range of 9-19 years. The median MMSE score 
was 29 with a range of 27-30 and the median BDI score 4 with a range of 1-11. 
Twenty two (91.7%) healthy participants were right-handed and 2 HC (8.3%) left-
handed. Regarding smoke habits one HC (4.2%) was smoker, 13 (54.2%) were non-
smokers and 10 (41.7%) were ex-smokers. The mean pack-year number were 8.33 (± 
15.8) with a range of 0-64 pack-years.  
The demographic characteristics and clinical characteristics of the two groups are 
shown in Table 1.   
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Table 1. Demographic characteristics of the participants groups 
 
Variable 
 
PD group  
(n=34) 
 
 
HC group                                
(n=24) 
 
 p 
 
Age (years) 
 
68.3 (±8.2) 
 
69.5 (±8) 
 
     NS 
Sex M/F=18/16 M/F=14/10      NS 
Education (years) 13  (9-20) 13 (9-19)      NS 
Handedness 31 (91.2%) R 
  3 (8.8%)   L 
22 (91.7 %) R 
  2 (8.3%) L 
     
Age of PD onset** 60 (35-75) -  
Disease duration (years)   9 (2-20) -  
MMSE score (/30) 29 (27-30) 29 (27-30)      NS 
BDI score (/63)   8 (0-17) 4 (1-11) p=0.005* 
PD type  
     akinetic-rigid 
     equivalent 
     tremor-dominant 
 
16 (47.1%)  
13 (38.2%)  
  5 (14.7%)  
-  
H&Y score  
    H&Y 1  
    H&Y 1.5 
    H&Y 2     
    H&Y 2.5  
    H&Y 3  
    H&Y 4 
2.5 (1-4) 
1 (2.9%)  
2 (5.9%) 
6 (17.6%)  
14 (41.2%)  
10 (29.4%)  
1 (2.9%)  
-  
UPDRS total 38.8 (±13) -  
UPDRS III 20.7 (± 6.7) -  
Side of predominance  
        R 
        L 
 
20 (58.8%)  
14 (41.2%)  
-  
Autonomic 
dysregulation*** 
        Yes 
        No 
 
24 (70.6%)  
10 (29.4%)   
-  
RBDSQ  5 (1-13) 2.5 (0-7)                                   p<0.001* 
L-dopa equivalent daily 
dose (LEDD, mg)**** 
577 (100-2417.5) -  
The values are described as Mean (±SD) or Median (Range) or as percentage of total, NS=non-
significant, *statistical significant at 0.05 level, **defined as onset of symptoms, ***orthostatic 
hypotonia and/or urinary bladder disorder and/or obstipation, ****calculated as suggested by 
Tomlinson et al. (Tomlinson et al., 2010) Abbreviations: PD=Parkinson’s disease, HC=healthy control, 
M/F: Male/Female Ratio, MMSE=Mini–Mental State Examination, BDI=Beck Depression Inventory, 
H&Y=Hoehn and Yahr, UPDRS=Unified Parkinson's Disease Rating Scale, RBDSQ=REM Sleep Behavior 
Disorder Screening Questionnaire, LEDD=L-dopa equivalent daily dose, R=right, L=left 
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2.2 Methods 
All participants (PD and HC) underwent an extensive neuropsychological assessment. 
The tests were administrated in a single session or in two sessions separated by a 
few hours and the test procedure lasted 1.5 hours or 2 hours altogether including an 
intermission. Patients with PD were also asked to report the time of their most 
recent drug intake, as they had to be in an ‘’on’’ state during the testing. After taking 
a medical, social and family history (regarding neurodegenerative diseases), all 
participants were neurologically examined. PD patients were clinical evaluated using 
the Unified Parkinson's Disease Rating Scale (UPDRS) and H & Y score.  
Unified Parkinson's disease rating scale (UPDRS) (Fahn et al., 1987) and Hoehn and 
Yahr score (see Appendix) 
The UPDRS is the most commonly used scale in clinical studies of Parkinson's disease 
and is used to follow the longitudinal course of Parkinson's disease. It is evaluated by 
interview and clinical observation and consists of the following six sections: 
 Part I: evaluation of mentation, reasoning, behavior, and mood 
 Part II: self-evaluation of the activities of daily life including speech, 
handwriting, dressing, eating, hygiene, falling, turning in bed and walking  
 Part III: clinician-scored motor evaluation  
 Part IV: complications of therapy i.e. dyskinesias and fluctuations 
 Part V: Hoehn and Yahr staging of severity of Parkinson's disease 
 Part VI: Schwab and England Activities of Daily Living scale 
A higher score indicates a greater severity of symptoms or signs. The patients were 
also classified in the Hoehn and Yahr stages, which is a five-stages-scale measuring 
the severity and progression of the disease and in the stages of the Modified Schwab 
and England Activities of Daily Living Scale, which is a self-rated assessment of 
overall everyday functional independence rated on an 11-point scale (see Appendix). 
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Mini Mental State Examination (MMSE) (max. score 30) (Folstein et al., 1975) 
The test includes questions to assess general cognitive function including orientation 
to time and place (from broadest to most narrow), immediate recall (repeating three 
terms), attention and calculation (spelling a word backwards or subtracting seven 
from one hundred), (delayed) recall of the three terms named at the beginning of 
the test, language (naming a watch and a pencil), repetition (of a phrase), ability to 
follow simple commands (from easy to most complex including drawing figure with 
interlocking pentagons shown). Higher scores indicate better cognitive function.  
Parkinson neuropsychometric dementia assessment (PANDA) instrument (max. score 
30) (Kalbe et al., 2008) 
The PANDA is a short test for the diagnostic assessment of cognitive impairment that 
was specifically developed for PD patients. The PANDA consists of a cognitive test 
part and a brief mood questionnaire, asking the patients how they were feeling 
lately. The test consists of the following 5 subtests covering a variety of domains 
such as verbal learning, verbal fluency, working memory and attention as well as 
visuospatial ability.  
Word pair associate learning task with immediate (subtest 1) and delayed recall 
(subtest 5): In these two subtests, which examine the ability of verbal learning and 
memory, the participant had to learn four pairs of common, semantically unrelated 
words (banana–suit, paper–frog, storm–ball and feather–scarf). These pairs were 
repeated three times in the immediate recall condition, each time followed by 
naming of one of these words and asking for the second word of the pair (e.g. 
banana–?) without revealing the participant the right answers in case of mistakes. 
The order of the words in the recall condition was different in each trial. The 
maximal raw score was 12 for the immediate recall. 
Alternating verbal fluency (subtest 2): This subtest includes cognitive domains like 
semantic memory (word retrieval), executive functions especially cognitive flexibility, 
attention and working memory, and speed of processing. The participants were 
asked to give as many examples of two semantic categories (e.g. the category 
animals and the category furniture) as possible within 1 min and to switch between 
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categories after each item. The number of correct words and switching errors were 
registered. There was no maximal raw score in this subtest.  
Visuospatial task or spatial visual thinking or spatial (mental) imagery (subtest 3): In 
this spatial imagery task (mental mirrors) three half-masked squares with dot 
patterns (diagonal folded) were shown and the subject had to find the pattern which 
emerges when removing the mask i.e. when the square was unfolded. The maximal 
raw score was 3. 
Working memory and attention task (subtest 4): In this task rows of numbers were 
read to the participants in a random order (e.g. „7–2–8–6“), and the subject had to 
repeat the numbers in a systematic order („2–6–7–8“). The number of items in the 
largest row correctly repeated was analyzed. The maximal raw score was 6. 
In the delayed recall condition (subtest 5) approximately 6–8 min after the 
immediate recall the four word pairs had to be completed in the same way (after 
naming the one of the words and asking for the second word of the pair). The 
number of correctly recalled words was registered. The maximal row score was 4 for 
the delayed recall condition. 
These raw scores were converted into the final subscores based on a table, which 
depends on age (≤59 years old or >60 years old), which in turn were added together 
to give the final score (maximal 30).  
Test zum kognitiven Schätzen (TKS) (max. score 16) (Brand et al., 2002) 
In this 16-item test, which involves many complex cognitive functions including 
activation and retrieval of specific semantic memories, working memory, planning 
and mental control, self-monitoring and self-correction, the participants were asked 
to estimate possible answers to questions in each of four categories: size, weight, 
quantity and time (4 questions in each category). Pictures of the objects were 
showed in the first three categories. All items required numerical responses. 
Participants were told that there was no exact answer for most questions so they 
had to make a reasonable guess what the answer would be. The estimation 
questions were asked out loud and participants gave their answers verbally. The 
participants could answer the questions using their preferred unit of measurement 
but the responses were converted to the same unit of measurement when scoring 
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the answers. Individuals were given as much time as necessary to make estimations. 
The answer had to be within a given range. Every answer below this range was noted 
as underestimated and every answer over this range was noted as overestimated. 
The maximal score was 16. 
Beck Depression Inventory (BDI) (max. score 63) (Beck et al., 1996) 
The BDI is a 21-question multiple-choice self-report inventory for measuring the 
severity of depression. The BDI-II version was used. It is composed of items relating 
to symptoms of depression such as hopelessness and irritability, feelings of guilt or 
of being punished, as well as physical symptoms such as fatigue, lack of appetite, 
weight loss, and lack of interest in sex. Higher scores indicate increasing depressive 
mood.  
Facial Emotion Recognition Test (Ekman 60 Faces Test) from Ekman and Friesen 
series (max. score 60) (Ekman & Friesen, 1976) 
In this test the subjects had initially to describe situations or circumstances in which 
people would experience the six basic emotions (happiness, anger, sadness, fear, 
disgust and surprise) in order to be sure that the participant had understand the 
meaning of these emotion words sufficiently. An example of a set of six expressions 
posed by a man was used for practice, to introduce the test.   
Black and white photographs of the faces of 10 people (6 female, 4 male) were 
selected from the Ekman and Friesen (1976) series. For each face, the poses 
corresponded each of the six emotions (happiness, anger, sadness, fear, disgust and 
surprise), giving a total of 60 photographs. These photographs were viewed on a 
personal computer (PC) monitor, presented individually for 5 seconds each, followed 
by a blank screen. The participants were also given labels with the six emotions 
written. The participants were then asked to indicate which of the six emotions was 
depicted in each photograph by verbally referring to the emotion labels or pointing 
to one of the six emotion labels. The participants could take as long as they needed 
to decide on the emotion. In the case of a wrong answer, this one was noted, 
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without revealing the right answer to the participant. An overall score of the 
expressions correctly recognized was calculated.    
Sniffin' Sticks odor identification test (max. score 16) (Hummel et al., 1997) 
The Sniffin’ Sticks test battery (Burghart, Wedel, Germany) is an olfactory test 
battery comprising of reusable felt-tip pens (‘‘sticks’’), which contain odorants from 
everyday life (mostly fruits and spices) dissolved in propylene glycol and which the 
subject has to sniff/smell. The pens were administered birhinally in front of the nose 
in a quiet, well-ventilated room to avoid any background smell interfering with the 
test odors. The participant should not have eaten at least fifteen minutes before the 
test. The participant was asked, before the beginning of the test, to evaluate his/her 
own smelling ability as normal, reduced or increased.  
 
Odor identification ability was measured by presenting 16 odorants in 
suprathreshold intensity and asking individuals to choose from a multiple (4)-forced 
choice format with verbal descriptions. Each stick was held 2 cm in front of the 
nostrils for 3 to 4 seconds, with an interval of 20 to 30 seconds between each stick. 
The participants had no time limit to decide on the choice responded to each smell. 
Olfactory scores were defined as the number of correct responses (0–16). 
REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) (max. score 13) 
(Stiasny-Kolster et al., 2007) 
The 10-item self-rated RBDSQ consists of questions regarding abnormal behavior 
during sleep phase with rapid eye movement (REM) sleep and covers the clinical 
features of rapid eye movement sleep behavior disorder (RBD). The questions ask 
about vivid dreams with aggressive or action-packed content, awareness of the 
moving of the arms and legs in sleep (“fights”), speaking, shouting or laughing while 
sleeping, doing gestures and complex movements that are useless during sleep (e.g. 
to wave or to salute) and falling off the bed as a consequence of this behavior. 
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Apathy Evaluation Scale (AES) (score 18-72) (Marin et al., 1991) 
The AES-S, a self-rated scale, was administered to all subjects. The scale consists of 
18 items and is aimed to provide global measures of apathy based on questions on 
interests, motivation, socialization, and how the individuals spend their time. The 
participant has to choose one answer between choices of a scale like "not at all", 
"slightly", "somewhat" or "a lot". Each item has a positive or negative meaning on 
the evaluation and concerns cognition, behavior, and emotion. The AES includes 
items evaluating cognitive evidence of apathy, for example, lack of interests, lack of 
curiosity and decrease in the importance attributed to goals or values (e.g health, 
finances or the welfare of others) as well as emotional evidence of apathy, for 
example shallow affect and emotional indifference. High AES scores indicate more 
apathy. In the original validation study of the apathy evaluation scale the mean (± 
standard deviation) score for healthy controls was 28 (±6) (Marin et al. 1991). 
Statistical analysis 
Analyses were carried out using the SPSS Version 17.0. Group differences in 
demographic, clinical and neuropsychological characteristics were analyzed with the 
independent two-sample Student’s t-test for normally distributed continuous 
variables, the Mann-Whitney U test for non-normally distributed variables and the 
chi-squared test for categorical variables. To test for differences regarding the 
performance in the FER task between the two groups, an ANCOVA analysis was 
conducted using as dependent variable the performance in the FER task and as 
independent the variables sex, age and group. The analysis was repeated to control 
for two possible (additional) confounding factors (BDI and Apathy scores), which had 
a significant difference between the two groups. A sensitivity analysis in the FER task 
was also conducted, excluding the subjects with specific characteristics. In addition, 
linear regression analysis was used to explore for possible associations of FER with 
demographic, clinical or neuropsychological characteristics. Statistical significant 
threshold for all analyses was set at p<0.05. 
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      3.    Results 
Performance on neuropsychological tasks 
Performance on PANDA test 
Thirty patients (88.2%) had a normal performance (equal or more than 18 points) 
and only two patients (5.9%) had a marginal score of 14, indicating according to the 
classification given by the test a probable dementia. Twenty-two HC (91.7%) had a 
normal performance and one (4.2%) a marginal performance of 14 points. Data from 
two patients and one healthy participant were missing on this test. There was no 
statistically significant difference in the performance on this test between the two 
groups (U=285, p=0.155). Regarding the subtests of the PANDA test, the groups 
showed no statistically significant difference. The scores of the two groups in the 
PANDA test and its’ subtests can be seen in Table 2. As verbal learning was defined 
the difference between the numbers of words recalled after the third trial of word 
pairs and the number of words recalled after the first trial (in subtest 1).  
Performance on TKS 
Twenty one patients (61.8%) had a normal performance (score ≥11), 12 patients 
(35.3%) a slight impaired one (score 8-10) and one patient (2.9%) impaired (score 
≤7). Seventeen HC subjects (70.8%) had a normal performance and 7 (29.2%) a slight 
impaired one. The two groups did not differ significantly on the cognitive estimation 
task (U=345.5, p=0.319). The scores of the two groups in the TKS can be seen in 
Table 2.  
Apathy evaluation scale 
The median score of the PD group on the apathy evaluation scale was 31.5 with a 
range of 18-29. The median score of the HC group was 24.50 with a range of 18-37. 
The two groups differed statistically significant, with the PD group exhibiting a higher 
apathy score (U=281, p=0.045).   
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Table 2. Performance on PANDA and cognitive estimation task 
 PD group  
 
HC group Test stats, p value 
PANDA total (/30) 24 (14-27) 25 (14-30) U=285, p=0.155 
   Immediate recall (/12)  8 (2-12) 8 (1-12) U=356, p=0.843 
   Verbal learning (recall 3-
recall 1) 
1 (-1-3) 1 (-1-3) U=358, p=0.859 
   Alternating verbal 
fluency                               
12 (7-19)                                        13 (9-20)                                     U=299, p=0.235 
   Switching errors 0 (0-2) 0 (0-3) U=307, p=0.106 
   Visuospatial task (/3) 2 (1-3) 2 (1-3) U=303, p=0.223 
   Working memory and       
attention task (/6) 
 
5 (4-6) 5 (4-6) U=318, p=0.357 
   Delayed recall (/4)                                     2 (0-4) 2 (0-4) U=331, p=0.514 
    
TKS total (/16)                                              11 (6-15)                           12 (8-15) U=345.5, p=0.319                                          
    size (/4)                                            3 (1-4)                                 3 (1-4)  
    weight (/4)    3 (1-4)   2.5 (1-4)  
    quantity (/4)                                3 (1-4)   3 (1-4)  
     time (/4)     3 (0-4)   4 (1-4)  
    
Test stats=test statistic of the Mann-Whitney test. (/max) =max. test score, when available 
shown in parenthesis. The performances are presented as Medians with Range. 
TKS=cognitive estimation task. *statistical significant at 0.05 level 
Performance on odor identification test 
The mean score of the PD group in the Sniffin’ Sticks test was 7.91 (± 2.98) correct 
responses (out of 16), while the mean score of the HC group was 11.42 (±2.13) 
correct responses. There was, as expected, a statistically significant difference in the 
scores of the two groups with the PD group having a significant lower score than the 
HC group (t=4.940, p<0.001). The same results were found when, the two 
participants, one HC who had a possible seasonal allergic rhinitis and a PD patient 
who had a nose surgery with probable reduced odor after the surgery, were 
excluded from the analysis (t=4.976, p<0.001). 
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Performance on Facial Emotion Recognition task  
The mean total performance of the PD group in the emotion recognition task was 
46.91 (±4.5). The HC group had a total mean performance of 49.63 (±4.4). In order to 
investigate, if there was a significant difference on the performances of the two 
groups in the FER task, an ANCOVA analysis was conducted using as dependent 
variable the performance in the FER task and as independent the variables sex, age 
and group. As shown in one-way ANCOVA, PD patients had on average a statistically 
significant lower score on the total FER task in comparison with HC (F=8.030, 
p=0.006).   
Concerning specific emotions, the PD group showed particularly an impairment in 
the recognition of surprise with a statistically significant lower score compared to HC 
(F=7.885, p=0.007). The difference in the identification of anger was close to 
statistical significance (p=0.07). As the two groups showed a statistically significant 
difference in BDI and Apathy score, the analysis was repeated to control for these 
two possible (additional) confounding factors (BDI and Apathy scores). The findings 
on FER task remained significant even after controlling for depression and apathy 
(F’=6.684, p=0.013 for the total FER score and F’=10.186, p=0.002 for the recognition 
of surprise). In addition, after excluding three subjects (2 PD patients, one HC) having 
a marginal score of 14 points in PANDA test (despite having a MMSE score of >27 
points and no clinical signs of dementia), the results did not change (F=6.671, 
p=0.013 for the FER total score and F=10.407, p=0.002 for the recognition of 
surprise). The scores of the two groups regarding the total and specific emotion 
recognition are shown in Table 3. 
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Table 3. FER performance of the PD and HC group 
 
 PD group 
(N=34) 
Mean (±SD) 
 
HC group (N=24) 
Mean (±SD) 
                                       
  F p F’ p’ 
FER total 46.91 (± 4.5) 49.63 (±4.4) 8.030 0.006*  6.684 0.013* 
happiness   9.76 (±0.43)  9.92 (±0.28) 2.786 0.101  3.954 0.052 
anger   8 (±1.74)  8.67 (± 1.24) 3.320 0.074  2.211 0.143 
sadness  7.85 (±1.6)  8.13 (± 1.6) 0.919 0.342  1.016 0.318 
fear  4.5 (±2.12)  4.96 (±2.33) 1.027 0.315   0.516 0.476 
disgust  8.68 (± 1.25)  8.79 (1.29) 0.160 0.691   0.022 0.882 
surprise  8.12 (±1.7)  9.17 (±1.09) 7.885 0.007* 10.186 0.002* 
ANCOVA for multiple factors controlling for age and sex; repeated after entering the 
factors BDI-score and apathy as covariates in the analysis (F’, p’) * Statistical significance 
at 0.05 level 
 
The accuracy for recognition of specific emotions (percentage of correct answers) in 
the PD and HC group respectively was as following (shown in Fig. 2): happiness 
97.65% and 99.17%, anger 80% and 86.67%, sadness 78.53% and 81.25%, fear 45% 
and 49.58%, disgust 86.76% and 87.92% and surprise 81.18% and 91.67%. Thus, the 
emotion more accurately recognized by both groups was happiness while fear was 
less accurate recognized also by both groups.  
 
Fig. 2.  Accuracy of FER of specific emotions in the two groups 
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In the PD group the most common misattribution of happiness was as surprise (75% 
of the wrong answers regarding this emotion), of anger as surprise 36.76%, of 
sadness as fear (47.95%), of fear as surprise (39.46%), of disgust as anger (53.33%) 
and surprise as fear (50%). In the HC group happiness was most common 
misinterpreted as surprise (100% of the wrong answers), anger as disgust (40.63%), 
sadness as fear (53.33%), fear as surprise (42.98%), disgust as anger 48.28% and 
surprise as fear (65%).  Thus, the most common misattributions of emotions in both 
groups were: happiness as surprise, sadness as fear, fear as surprise, disgust as anger 
and surprise as fear. 
In PD patients, possible associations between FER and potential predictors were 
assessed using linear regression analysis. FER was associated with chronological age 
(β=-0.294, p=0.001, CI 95% -0.462, -0.126) and age of onset of the disease (β=-0.194, 
p=0.012, CI 95% -0.342, -0.046). With increasing age PD patients showed a worse 
total recognition of facial emotions and specifically the increase of the patients’ age 
by one year reduced on average the total FER score by 0.294. As seen in Fig. 3, the 
effect of age on FER performance was more pronounced in the PD patients 
compared to controls. In a regression analysis within all subjects, adding age to 
group classification (PD or control) as predictor factors leaded to a 15% increase in 
the total variance of FER explained by the model (adjusted R2 = 0.205, p= 0.002) 
compared to the analysis using as predictor factor the disease status alone. Similarly, 
with increasing age of onset of the disease, patients had a worse performance on the 
FER task and specifically the increase of the age of onset of the disease by one year 
reduced the total FER score on average by 0.194. 
42 
 
 
Fig 3. Effect of age on FER-performance in PD and HC 
  
On the other hand, FER was not associated with patients’ characteristics like gender, 
education and handedness. FER was also not predicted by disease characteristics like 
disease disability measured by UPDRS total score, motor impairment measured by 
UPDRS III, disease duration, disease severity measured by H & Y score, disease most 
affected body side, type of PD, hypomimia as quantified by UPDRS item III, (vertical) 
restriction of ocular movements (clinically assessed), freezing of gait, postural 
instability, orthostatic dysregulation and REM sleep behavior disorder.  
Regarding facial emotion recognition and olfaction, there was a slight positive 
association (β=0.45) found, which was close to statistical significance (p=0.087, CI 
95% -0.069, 0.969). Furthermore, when olfactory function was entered next to group 
classification as predictor factor into a regression analysis model within all 
participants, the prediction of FER performance was considerably improved 
(adjusted R2= 0.135, p= 0.025 versus adjusted R2=0.069, p=0.026 in the model using 
as predictor factor the group classification alone). 
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In addition FER was not also predicted by cognitive performance (MMSE, 
performance on PANDA), executive functions measured by PANDA subtests like 
immediate and delayed recall, visuospatial ability and working memory or 
performance on the cognitive estimation task. Verbal fluency, showing a slight 
positive association with FER, only approached statistical significance (β=0.524, 
p=0.08, CI 95% -0.071, 1.119) but did not reached it. There was also no relationship 
found between FER and BDI or Apathy.  
When examining for possible outliers in the FER task, there were two patients, who 
obtained scores more than 2 SD below the control mean of facial emotion 
recognition. These patients were not distinguished by any specific factor, such as 
age, education, duration or severity of PD, cognitive performance, depression or 
apathy, and dosage or type of medication.  
 
      4.    Discussion  
In the present study, a deficit in facial emotion recognition in PD patients compared 
with sex- and age-matched healthy controls was shown, consistent with previous 
studies, which showed a recognition deficit in all or some of the so-called basic 
emotions in PD (Sprengelmeyer et al., 2003; Yip et al., 2003; Dujardin et al., 2004; 
Suzuki et al., 2006; Lawrence et al., 2007; Ariatti et al., 2008; Clark et al., 2008; 
Ibarretxe-Bilbao et al., 2009; Assogna et al., 2010; Herrera et al., 2011; Baggio et al., 
2012; Narme et al., 2013; Buxton et al., 2013; Saenz et al., 2013; Hipp et al., 2014).  
This FER impairment of the PD group in the present study remained significant after 
controlling for depression and apathy scores, which were found to have a statistically 
significant difference between the two groups. 
Impaired facial emotion recognition in PD may rely on anatomical connections of the 
basal ganglia, which seem to play an important role in recognizing emotions from 
facial cues, as part of a distributed network of cortical and subcortical structures 
(Adolphs, 2002a). Both dorsal and ventral structures of the basal ganglia, which 
degenerate in PD, have functional connections with the amygdala (Sprengelmeyer et 
al., 1998; Adolphs, 2002a), a limbic structure traditionally linked to facial emotion 
recognition. The amygdala has been shown to be affected in PD in pathological and 
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neuroimaging studies (Harding et al., 2002; Braak et al., 2003a; Yoshimura et al., 
2005; Baggio et al., 2012). There are also topographic connections between the basal 
ganglia and the prefrontal cortex, including the orbitofrontal cortex, areas that have 
been shown to be related with the facial emotion recognition (Sprengelmeyer et al., 
1998; Adolphs, 2002a; Ibarretxe-Bilbao et al., 2009). The orbitofrontal cortex is the 
limbic portion of the frontal association cortex (Porrino et al., 1981) and is also 
associated with medial temporal limbic structures, which are considered to be 
critical for the processing of internal states such as affect and motivation (Miller and 
Cohen, 2001). Thus, the basal ganglia contribute to emotion recognition from faces 
(Adolphs, 2002b; Cheung et al., 2006) possibly both directly and indirectly through 
their connections with brain areas important for emotional processing, including the 
orbitofrontal cortex and the amygdala (Adolphs, 2002b; Péron et al., 2012).  
The facial emotion recognition deficit in PD, expressing possibly a general emotional 
information processing deficit, may reflect a dysfunction of the cortical-basal 
ganglia-thalamic-cortical functional loops. The dopamine depletion that occurs in PD 
can lead to dysfunction of the limbic loop linking areas of the basal ganglia (most 
importantly the ventral striatum) to the orbitofrontal cortex (Lawrence et al., 2007; 
Péron et al., 2012), which could explain a FER deficit. Indeed, parts of the limbic loop 
(posterior parts of the ventral putamen) have been shown to be affected in PD 
patients in more advanced stages of the disease in neuroimaging studies (Morrish et 
al., 1996). As many studies showing a FER deficit included only patients early in the 
disease course (Sprengelmeyer et al., 2003; Dujardin et al., 2004; Suzuki et al. 2006), 
it can be assumed that these loops can be affected quite early in the course of the 
disease.    
Most of the areas, which are considered to be involved in facial emotion recognition, 
namely the nigrostriatal system, the amygdala, the insular cortex and almost all 
cortex areas in later stages of the disease are known to be affected as a result of the 
PD-related pathology (Braak et al., 2003a). In this context should also be noted that 
brain pathology in PD affects according to a predictable ascending topographical 
sequence limbic areas, which constitute key neural substrates for the facial emotion 
recognition function, early in the disease course (Braak et al., 2003a). Thus, it might 
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be of interest for future studies to assess FER as a possible pre-motor sign of the 
disease. 
Diederich et al. (Diederich and Parent, 2012) proposed that FER impairment in PD 
patients could be due to impairment of ancient (archaic) neural networks involving 
the basal ganglia. They proposed that the dysfunction of two types of archaic neural 
networks could be involved in PD: those involving sensory pathways i.e the olfactory 
system and the subconscious visual retino-tectal system and those concerning 
motility i.e gait automatisation and REM sleep disorder. The retinotectal visual 
system (RTVS) is an ancient subconscious visual pathway that extents from the retina 
to the superior colliculus via thalamus (pulvinar nuclei), connected by a closed loop 
to the basal ganglia (the substantia nigra pars reticulate), which is mainly responsible 
for gaze automatism and subconscious, rapid track appreciation of a face (De Gelder 
et al., 2005). The RTVS is of great importance to the so-called ´´blindsight vision´´ or 
vision without conscious appreciation (Goodale and Milner, 1992; Crick and Coch, 
1995; Morris et al., 1999) and could thus play a role in the recognition of emotions of 
faces.  
A less direct explanation of the facial emotion deficits in PD is that of the ´´reverse 
stimulation´´ (Goldman and Sripada, 2005). In everyday social interactions, the 
recognition of emotions involves a ´´facial feedback´´, in which the perceiver mimics, 
in a way, the emotion expressed in the partner´s face (Dimberg et al., 2000; Adolphs 
2002a). This muscular activity helps the perceiver to experience to some extent and 
to categorize this emotion (Stel and van Knippenberg, 2008). Therefore, the deficits 
in facial emotion recognition in PD patients can be partially attributed to their 
decreased ability to mimic displayed emotions (Smith et al., 1996). However, in our 
study FER was not associated with the degree of hypomimia in PD patients. 
Interesting is to investigate closer, whether the loss of ability to recognize an 
emotion is associated with the inability to experience that emotion, a phenomenon 
called empathy (Assogna et al., 2008). 
Regarding specific emotion impairment, a specific deficit for the emotion of surprise 
in PD patients was found in the present study. A significant difference (p<0.01) in 
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recognizing surprise was also found in the study of Clark et al. (Clark et al., 2008), 
and was replicated in the study of the same authors (Clark et al., 2010), which 
included a sub-sample of the original cohort, observed in the patients with right side 
of motor onset (driven by left hemisphere pathology).  In the neuroimaging study of 
Ibarretxe-Bilbao et al. (Ibarretxe-Bilbao et al., 2009), PD patients showed also a 
statistically significant lower score in the recognition of surprise. In the study of 
Baggio et al. (Baggio et al., 2012), which primarily explored the neural substrates of 
FER in PD patients using fMRI, an impairment in the recognition of surprise only 
approached statistical significance (p=0.07). Compared to the group of the present 
study, the PD group in the studies of Clark et al. (Clark et al., 2008), Baggio et al. 
(Baggio et al., 2012) and Ibarretxe-Bilbao et al. (Ibarretxe-Bilbao et al., 2009) was on 
average younger and had a slightly lower disease severity (measured by Hoehn and 
Yahr score) and shorter disease duration while other demographic characteristics 
like MMSE and education were comparable. In the study of Buxton et al. (Buxton et 
al., 2013) the PD group only approached significance for poorer accuracy at 
recognizing surprise (p=0.06) at the moderate level of difficulty of the FER task, while 
there was no significant difference found at the easy level of the task. At this point 
should be noted, that a lot of studies did not test for surprise (Dewick et al., 1991; 
Jacobs et al., 1995; Madeley et al., 1995; Breitenstein et al., 1998; Tessitore et al., 
2002; Dujardin et al., 2004a; Ariatti et al., 2008; Assogna et al., 2010; Cohen et al., 
2010; Narme et al., 2011; Wieser et al., 2012; Saenz et al., 2013).   
Concerning the neural substrates of the recognition of surprise, there are a few data 
on this issue, which are mostly collected by the assessment of the five other basic 
emotions. Bilateral damage to the amygdala has been shown to be related with a 
deficit in the recognition of fear and surprise (after bilateral amygdala damage in the 
studies of Adolphs et al. (Adolphs et al., 1994; Adolphs et al., 1995) and after partial 
bilateral amygdalotomy in the studies of Young et al. (Young et al., 1995; Young et al. 
1996)).  Posamentier and Abdi (Posamentier and Abdi, 2003) commented that the 
expression of surprise has strong resemblances with the emotion of fear including 
wide open eyes and mouth.  Indeed, in our study the most commonly misattribution 
of surprise in both PD patients and healthy participants was as fear. Furthermore, 
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Posamentier and Abdi suggested that as the emotional states are dynamic, the 
emotion of surprise can be defined as a “transitory emotion”, that can quickly turn 
into fear (negative emotion) or happiness (positive emotion), depending on the 
nature of the stimuli (Posamentier and Abdi, 2003). A neuroimaging study in normal 
subjects (Kim et al., 2003) showed inverse fMRI activation patterns in amygdala and 
medial prefrontal cortex, depending upon whether the subjects interpreted 
surprised facial expressions positively or negatively. More negative interpretations of 
surprised faces were associated with greater activation in the right ventral amygdala, 
while more positive interpretations with greater activation in the ventral medial 
prefrontal cortex (Kim et al., 2003). These areas are known to be affected from PD 
related pathology (Braak et al., 2003a), providing a reasonable explanation of this 
specific emotion impairment in PD patients. However, whether these activation 
patters are disturbed in PD remains to be elucidated. Moreover, PD patients may 
exhibit difficulties in resolving visual perceptional ambiguity (Diaz-Santos et al., 
2015), possibly contributing to impaired surprise recognition in the PD group, which, 
as mentioned, can be an ambiguous stimulus. The recognition of surprise is also 
shown to be impaired in Huntington´s disease (Sprengelmeyer et al., 1996), a disease 
affecting the basal ganglia and in individuals with Korsakoff´s syndrome (Montage et 
al., 2006), which is characterized by frontolimbic pathology.  The general and specific 
neural circuitry underlying recognition of rather positive emotions (like happiness 
and surprise) is, generally, far less well understood than for many negative emotions 
(Kringelbach and Berridge, 2010) and could be the aim of future studies.  
Anger was worse recognized in the PD group compared to the healthy control group, 
but this difference was only close to statistical significance (p=0.06). Notably, the 
recognition of anger has been shown to be impaired in PD patients in some previous 
studies (Sprengelmeyer et al., 2003; Lawrence et al., 2007; Clark et al., 2008).  The 
impairment in recognizing anger has been linked to dysfunction of ventral striatum 
(Calder et al., 2004), providing a possible explanation for this finding in PD patients. 
The emotion most accurately recognized by both groups in the present study was 
happiness while fear was least accurately recognized. Across studies happiness was 
the emotion most accurately recognized and fear the one least accurately recognized 
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by both PD and healthy participants (Adolphs et al., 1998; Kan et al., 2002; 
Sprengelmeyer et al., 2003; Ariatti et al., 2008; Suzuki et al., 2008; Clark et al., 2008; 
Ibarretxe-Bilbao et al., 2009; Narme et al., 2013; Buxton et al., 2013; Saenz et al., 
2013; Hipp et al., 2014). Facial expressions of fear are, indeed, even among the 
healthy population the most difficult to recognize (Russell, 1994; Biehl et al., 1997; 
Ruffman et al., 2008).  The most common misattributions of emotions in both our 
groups were: happiness as surprise, sadness as fear, fear as surprise, disgust as anger 
and surprise as fear. The only emotion, which the two groups misinterpreted 
differently, was anger: the PD group as surprise while the HC group as disgust.  
Facial emotion recognition impairment was found in our study to be associated with 
chronological age and age of onset of PD. Older PD patients tended to recognize 
worse facial emotions. A significant correlation of the total FER score with age of PD 
patients was also found in the study of Adolphs et al. (Adolphs et al., 1998), in the 
study of Baggio et al. (Baggio et al., 2012) (r=-0.35, p=0.028) and in the study of 
Mart´ınez-Corral et al. (Mart´ınez-Corral et al., 2010) (r=-0.312, p=0.033). This finding 
is consistent with the observations that recognition of emotion, especially of 
negative emotions like anger, sadness and fear and to a less extent of happiness and 
surprise, is less accurate in older healthy adults compared to young adults (Ruffman 
et al., 2008). This can be attributed to the age-related changes found in areas 
associated with facial emotion recognition like the frontal and temporal regions 
(Bartzokis et al., 2001; Raz et al., 2005), the orbitofrontal cortex (Convit et al., 2001; 
Tisserand et al., 2002) and the amygdala (Mu et al., 1999; Allen et al., 2005). PD 
neuropathological changes, which according to Braak et al. (Braak et al., 2003a) 
affect these areas, in combination with age-related changes could explain the 
observed association of facial emotion recognition with chronological age. From 
another point of view, the decline in general cognitive resources, observed with 
increasing age, such as slowed processing speed or decreased working memory 
capacity (Philips and Henry, 2005), could partially explain a worsening in the 
performance in FER with increasing age.  Although it is difficult to isolate the effect 
of age at disease-onset from the effect of chronological age, PD patients with a 
higher age at disease onset also had a worse performance in the FER task in our 
49 
 
study.  It has been suggested that early-onset and late-onset subtypes of PD may 
demonstrate different phenotypes, since young-onset patients are more likely to 
carry genetic mutations responsible for their clinical phenotype even in the absence 
of positive family history, whereas late-onset patients are more likely to represent 
cases with more multifactorial etiology in which neuroprotective mechanisms have 
been exhausted and the harmful effects of yet unknown exogenous factors have 
summed up or are superimposed on natural aging processes leading to the 
manifestation of the disease (Pagano et al., 2016). A strict classification of symptoms 
to different subtypes according to age of disease onset has not yet been possible, 
although the severity of motor and non-motor features seem to increase with age of 
onset (Pagano et al., 2016). Later age of onset is also considered a risk factor for 
cognitive decline in PD (Hobson and Meara, 2004).  
We found that olfactory function along with PD diagnosis predicted worse facial 
emotion recognition performance within all study participants. Our finding is of 
special interest as, to the best of our knowledge, an association of olfaction with FER 
has not been previously reported in PD. As facial emotion recognition and olfaction 
share common neuroanatomical substrates, the association between them is 
plausible. Indeed, the cortical nuclei of the amygdala, a structure traditionally 
involved in FER, are closely linked to the olfactory bulb and have a well-known 
involvement in olfactory function (Harding et al., 2002). Furthermore, the 
orbitofrontal cortex, an important neural substrate of FER, receives projections from 
the primary olfactory cortex (piriform cortex) (Doty, 2012; Soudry et al., 2011). The 
orbitofrontal cortex and insular cortex, which have been linked to perception of 
facial expression of adverse stimuli, in particular that of disgust (Phillips et al., 1997; 
Rolls, 2015), are considered to be involved in a higher level processing of olfactory 
and gustatory stimuli. Functional brain imaging studies (Levy et al., 1997) showed 
activation of these same areas in response to olfactory stimuli, in some studies 
dependent on valence (pleasantness or unpleasantness) of stimuli (Fulbright et al., 
1998; Zald & Pardo, 1997). At a behavioral-cognitive level, emotional cues carried by 
odors may be a potent factor in regulating the perception of facial emotion. 
Olfactory stimuli could possibly pre-activate visual representations of emotional 
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expressions through intersensory integration processes (Leleu et al., 2015). Another 
explanation could be that the odors involve the motor system by activation of mirror 
neurons (Gallese & Goldman, 1998). Odors could provoke facial microreaktions, 
which may facilitate the recognition of facial expressions (Leleu et al., 2015). 
Olfactory information may also participate in recognition of emotion, for example by 
facilitating a classification in olfaction-related emotional categories (e.g. pleasant vs. 
unpleasant) (Leleu et al., 2015). Thus, the perception of facial expressions is not a 
purely visual process but also integrates cues from other sensory modalities, 
including olfaction.  
All the above mentioned areas, namely the amygdala, the orbitofrontal and insular 
cortex, involved in both FER and olfaction are affected from PD-related pathology 
(Braak et al., 2003a; Harding et al., 2002). The functional connections of these areas 
imply that dysfunction of one area, as a result of degeneration, can lead to 
dysfunction of the other. From another point of view, according to the hypothesis 
proposed by Diederich & Parent (Diederich and Parent, 2012) both sensory deficits, 
FER and olfactory function, could result from an impairment of phylogenetically 
ancient neural networks in PD involving sensory pathways i.e the olfactory system 
and the subconscious visual retino-tectal system, which is mainly responsible for 
gaze automatism and subconscious, rapid track appreciation of a face. 
The facial emotion recognition impairment was not associated with any 
demographical characteristic of the patients like gender or education in the present 
study consistent with other previous studies (Adolphs et al., 1998; Clark et al., 2008; 
Buxton et al., 2013; Saenz et al., 2013). It was also not associated with handedness, 
although most participants were right-handed and conclusions should be drawn 
carefully on this matter. FER was also not associated with disease characteristics like 
disease disability measured by UPDRS total score and severity of motor impairment 
measured by UPDRS III in accordance with other studies (Dujardin et al., 2004a; 
Ariatti et al., 2008; Saenz et al., 2013). On the other hand, in the study of Buxton et 
al. (Buxton et al., 2013) the UPDRS III score was significantly negatively associated 
with the overall performance in the FER task. Lawrence et al. (Lawrence et al., 2007) 
showed also a significant negative correlation between the degree of motor 
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impairment and recognition of sadness. In these two studies (Lawrence et al., 2007; 
Buxton et al., 2013) the patients were slightly more severely affected compared to 
the PD patients of the present study. Moreover, Pell and Leonard (Pell and Leonard, 
2005) found a marginally significant negative correlation between the degree of 
motor symptoms and the recognition of disgust. Sprengelmeyer et al. 
(Sprengelmeyer et al., 2003) reported opposite results with more apparent facial 
emotion recognition impairment in patients with less severe motor impairment. FER 
was not associated with disease duration like in many previous studies (Clark et al., 
2008; Assogna et al., 2010; Baggio et al., 2012; Buxton et al., 2013) or disease 
severity measured by H & Y score also in accordance with other studies (Clark et al., 
2008; Baggio et al., 2012; Buxton et al., 2013). Across studies, the level of emotion 
recognition deficit does not appear to be related to the level of motor disability. 
However, it should be noted that the patients included in the studies exhibited mild 
to moderate bilateral disease, and other conclusions may have been drawn if most 
severely affected patients were included (Gray and Tickle-Degnen, 2010). No 
association was also found with type of PD (akinetic-rigid, equivalent or tremor-
dominant) or the disease most affected body side in the present study. Regarding 
the association between the emotion recognition deficit of PD patients and the 
predominant side of motor symptoms, Yip et. al (Yip et. al, 2003) showed an 
impairment in the recognition of all emotions in patients with bilateral motor 
symptoms, with the recognition of fear and sadness being more impaired, while the 
right-sided PD patients showed an impairment in the recognition of all emotions, 
especially in the recognition of sadness and disgust except happiness. Furthermore, 
Ariatti et al. (Ariatti et al., 2008) found that right-side PD patients were impaired in 
recognition of fear whereas left-side patients in the recognition of sadness. Clark et 
al. (Clark et al., 2008) showed that PD patients with left side of onset of symptoms 
(driven from right-side pathology) show impairment in the facial recognition of anger 
while those with right side onset (driven from left-side pathology) of surprise. Thus, 
although the right hemisphere is traditionally thought to be more active than the left 
in processing of emotions (Adolphs et al., 1996), a clear lateralization in recognizing 
of facial emotions has not been proved. While it might be considered, that 
hypokinesia and especially hypomimia (the ability to show emotions with facial 
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expressions) in PD patients could be associated with impaired ability to recognize the 
facial emotions of others (Assogna et al., 2010), this was not the case in our study in 
which FER was not associated with the degree of hypomimia. FER was also not 
associated with freezing of gait, postural instability, orthostatic dysregulation and 
REM sleep behavior disorder. A possible association with these clinical parameters, 
to the best of our knowledge, was not examined before.  
Facial emotion recognition was also not associated with the dopaminergic 
medication in the present study like in other studies (Baggio et al., 2012; Hipp et al., 
2014), and in the meta-analysis of Gray and Tickle-Degner (Gray and Tickle-Degner, 
2010). Dopamine transmission plays an important role in the modulation of 
emotional responses. Tessitore et al. (Tessitore et al., 2002) demonstrated in a study 
using functional MRI in healthy subjects and PD patients that the activation of 
amygdala in response to fearful emotional stimuli was absent in PD patients during 
the hypodopaminergic state (i.e., > or =12 hours after their last dose of 
dopaminergic treatment). Dopamine repletion partially restored this response in PD 
patients. Accordingly, Sprengelmeyer at al. (Sprengelmeyer at al., 2003) showed that 
the recognition of disgust was more impaired in unmedicated (drug-naive) compared 
to medicated PD patients. In another functional study the acute treatment with D2 
receptor antagonists reduced the amygdala activity in fMRI in healthy subjects in 
response to affective pictures (Takahashi et al., 2005). Furthermore, Lawrence et al. 
(Lawrence et al., 2002) showed that acute dopaminergic blockade in healthy 
volunteers resulted in a transient disruption of the recognition of facial expressions 
of anger, while leaving intact the recognition of other facial expressions. The same 
authors (Lawrence et al., 2007) showed an impaired recognition of facial expressions 
of anger in a group of PD patients transiently withdrawn from dopamine 
replacement therapy. Assogna et al. (Assogna et al., 2010) showed a positive 
correlation of LEDD (daily l-dopa dosis) with only the recognition of fear. On the 
other hand, Hipp et al. (Hipp et al., 2014) and Baggio et al. (Baggio et al., 2012), 
showed no correlation of FER with the levodopa medication. Gray and Tickle-Degner 
(Gray and Tickle-Degner, 2010) in their meta-analysis, although they did find that the 
emotion recognition impairment (effect size) was greater in patients in a 
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hypodopaminergic state, consistent with the assumed role of dopamine in emotion 
regulation and recognition, the difference in the impairment in facial emotion 
recognition between medicated patients and patients at hypodopaminergic state at 
the time of testing was not significant. Based on these results, is thus plausible to 
hypothesize that an impaired FER is unlikely to be explained by a sole dopamine 
deficiency. 
The identification of emotions can be seen as a complex cognitive process, 
demanding the integrity of many cognitive domains such as visual attention, 
visuospatial perception, working memory and language (Assogna et al., 2008).  The 
FER performance was, however, not associated with the cognitive performance of 
patients or executive functions like immediate and delayed recall, verbal fluency and 
working memory (as covered by the PANDA test) in the present study. Furthermore, 
after excluding the three subjects (2 patients, one healthy control) having a marginal 
score of ≤14 points in PANDA test, indicating a probable dementia according to the 
classification given by the test, the results did not change. It has to be noted that 
these participants had a MMSE score of >27 points and lacked any clinical signs of 
dementia while their score (14 points) in PANDA test was very close to the test limit. 
Moreover, our study was the first to show the lack of association between FER and 
performance on the cognitive estimation test, which is generally considered to be a 
measure of executive function, demanding retrieval of semantic memories, working 
memory and self-monitoring. The results regarding an association of FER with 
cognitive and executive functions were quite inconsistent in a small number of 
previous studies, which used heterogeneous methods of assessment and focused on 
different aspects of executive functions. Adolphs et al. (Adolphs et al., 1998) and Kan 
et al. (Kan et al., 2002) did not found any correlation of facial emotion recognition 
with MMSE score (in patients with MMSE score greater or equal to 23). Accordingly, 
Lawrence et al. (Lawrence et al., 2007) and Pell and Leonard (Pell and Leonard, 2005) 
failed to show any correlation between facial expression recognition and cognitive 
scores. Moreover, Ariatti et al. (Ariatti et al., 2008) found no correlation with tasks 
exploring frontal dysfunction (Frontal Assessment Battery and modified Card Sorting 
Test). Saenz et al. (Saenz et al., 2013) did not find a significant correlation of FER 
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performance with attention and executive function tests (digit and spatial span tests, 
the similarities and picture completion subtests of the Wechsler Adult Intelligence 
Scale WAIS III, the Stroop test) as well as language (verbal fluency) tests. Alonso-
Recio et al. (Alonso-Recio et al., 2014 b, c) showed also no correlation of FER with 
working memory or selective attention of PD patients. On the other hand, Assogna 
et al. (Assogna et al., 2010) found a positive correlation of total emotion recognition 
score with MMSE score, with immediate and delayed words recall, phonological 
verbal fluency and stroop interference time scores. Moreover, Dujardin et al. 
(Dujardin et al., 2004a) reported a relationship between the facial emotion 
recognition and the overall executive score (including tests of verbal fluency and 
working memory i.e. stroop test, letter and number sequencing task, crossed tapping 
test). Hipp et al. (Hipp et al., 2014) showed that lower scores in Frontal Assessment 
Battery, representing executive dysfunction, correlated with a worse recognition of 
anger in patients with early PD. It must be noted, that the tests evaluating executive 
functions in our study permitted only a general comparison on this issue and were 
less specific than these used in other studies, since they have been used to capture 
relevant cognitive impairment in PD. As the participants in our study and in most 
studies, were selected to be cognitively intact, it might well be that associations with 
cognitive parameters would have arisen, if patients with more pronounced cognitive 
deficits were included. The lack of an association between facial emotional 
processing ability and other specific cognitive domains in cognitively intact patients 
points to the fact that impairment of emotional recognition is a distinct non-motor 
feature of PD.   
FER was also not associated with visuospatial ability in our study.  The results of the 
studies, which used various tests assessing the visuospatial ability, are again not 
consistent. Yip et al. (Yip et al., 2003) showed that visual organization ability 
(measured by the Hooper Visual Organisation Test) positively predicted the ability to 
identify emotions from visual stimuli in patients with bilateral PD while visual 
attention (measured by the Ballons Test) did not. Saenz et al. (Saenz et al., 2013) 
found a significant correlation between the scores of FER and Brixton Spatial 
Anticipation Test (a test of visuospatial ability) but not with a test evaluating visual 
neglect (Bells test). Marneweck et al. (Marneweck et al., 2014b) suggested that the 
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impaired ability to perceive visual form (measured by a test using variable 
modulations of a perfect circle) is likely to contribute to the impaired ability to 
perceive facial expressions of emotions in PD. On the other hand, in the study of 
Adolphs et al. (Adolphs et al., 1998) and Clark et al. (Clark et al., 2008) FER in PD 
patients had no correlation with the Benton facial recognition test, one of the most 
commonly used test among studies, in which the participant is asked to discriminate 
between faces of unfamiliar people with neutral expressions. Kan et al. (Kan et al., 
2002) showed again no correlation of FER from both static and moving facial stimuli 
with visuospatial function (using Rey-Osterrieth Complex Figure and Facial Identity 
discrimination test). Dujardin et al. (Dujardin et al., 2004) showed also no correlation 
between FER and visuospatial perception. Thus, most studies found no significant 
group differences regarding visuospatial ability, suggesting that the facial emotion 
recognition deficit in PD exists beyond a general deficit in face processing (Gray and 
Tickle-Degnen, 2010). 
The facial emotion recognition in the present study, like in many previous studies, 
was not associated with the depression score of the PD patients. The present study, 
as most studies, excluded severe depressed PD patients. Most studies (Adolphs, 
1998; Dujardin et. al., 2004a; Pell and Leonard, 2005; Ariatti et al., 2008; Buxton et 
al., 2013; Saenz et al., 2013) using Beck Depression Inventory or Hamilton 
Depression Inventory, reported no correlation between depression scores and facial 
emotion recognition in PD patients.  Furthermore, Lawrence et al. (Lawrence et al., 
2007), using the Beck Depression Inventory in a group of patients withdrawn from 
dopamine replacement therapy, reported also no significant correlation. However, in 
the study by Clark et al. (Clark et al., 2008) and Baggio et al. (Baggio et al., 2012) 
depression score was negatively correlated with FER. In the study of Kan et al. (Kan 
et al., 2002) was found a positive correlation between depression score (measured 
by the Zung Self-Rating Depression Scale) and the face recognition of fear while no 
correlation was found regarding the total score or the other facial emotions. The 
Meta-analysis of Gray and Tickle-Degner (Gray and Tickle-Degner, 2010) confirmed 
that the emotion recognition deficit in PD exists independent of depression. Thus, 
although affective states may influence sensitivity to and selective attention towards 
facial emotional expressions (Bourke et al., 2010) and emotion recognition 
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impairment for all basic emotions except sadness has been shown in the depression 
literature (Dalili et al., 2015), this does not seem to be the case in PD.  
In addition, FER was not associated with apathy in our patients, consistent with the 
study of Saenz et al. (Saenz et al., 2013) which examined this issue. On the other 
hand, Robert et al. (Robert et al., 2013) found a significant negative correlation 
between apathy scores and performances on the FER task and Mart´ınez-Corral et al. 
(Mart´ınez-Corral et al., 2010) showed that non-demented, non-depressed PD 
patients with apathy scored significantly worse in the FER than PD patients without 
apathy and healthy controls.  
It is a fact, that the various previous studies on facial emotion recognition in PD 
showed inconsistent results. This inconsistency can be attributed to variations in 
methodology across studies. Across studies there has been heterogeneity in the 
methods of assessment of facial emotion recognition, in patient samples, in age, 
cognitive status, disease severity and duration, or medication and the number of 
participants recruited were relative small (Gray and Tickle-Degnen, 2010; Leppanen, 
2006). Concerning the methods used to assess facial emotion recognition, the most 
commonly used task was the Pictures of Facial Affect by Ekman & Friesen (Ekman & 
Friesen, 1976) as in the present study. Other common stimuli tests were the 
Japanese and Caucasian Facial Expressions of Emotion series (Matsumoto & Ekman, 
1988) used in six comparisons and a subtest of the Florida Affect Battery (Bowers et 
al., 1991) used in five comparisons. The time of presentation of the visual stimuli 
varied also, even among the studies using the same test, ranging between three to 
ten seconds or was unspecified. In the present study, the time was chosen to be five 
seconds, in order to be sufficient for the patients to give an answer regarding the 
emotion depicted. Another factor that can have contributed to the inconsistency of 
the results of studies has been the variation across studies regarding task that was 
used and task difficulty.  Most of the studies used identification tests (using labeling 
of emotions), while a lot of studies discrimination tests (for example deciding which 
of two photographs matches a named emotion or deciding whether two pictures 
expressed the same emotion) and a small number of studies used rating tasks (i.e. 
rating the extent of the depicted emotion) (Gray & Tickle-Denger, 2010). Concerning 
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task difficulty, the studies from Clark et al. (Clark et al., 2008) and Suzuki et al. 
(Suzuki et al., 2006) have controlled for task difficulty, while previous studies did not 
consider this factor. Dujardin et al. (Dujardin et al., 2004a) showed that the PD group 
was less accurate in recognizing visual stimuli of sadness, anger and disgust 
compared to the healthy controls, regardless of the level of reduced intensity of the 
stimuli. Saenz et al. (Saenz et al., 2013), who used hybrid faces created by software 
allowing variation of the emotion intensity depicted, found no significant difference 
between the recognition of low and high levels of intensity of stimuli in the PD 
group. On the contrary, Suzuki et al. (Suzuki et al., 2006) found a selective 
impairment in the recognition of disgust, only on the difficult task level. Buxton et al. 
(Buxton et al., 2013), using subtle expressions of emotion, showed that although PD 
patients identified emotional expressions on Ekman and Friesen phototypical test as 
accurately as the control group, as the facial expressions of emotion became more 
subtle, the PD group was significantly less accurate at identifying disgust in the 
moderate level, sadness at the most difficult level and happiness at both levels of 
subtlety. The emotions commonly tested across studies were anger, disgust, fear, 
happiness, sadness, surprise or a combination thereof. Not all studies tested for all 
the basic emotions. Another important limit of methods used for evaluating facial 
emotion recognition was the absence of other clues (such as verbal tone, gestures, 
body posture) of everyday life context, which can help the subjects in recognizing 
emotions (Assogna et al., 2008; Paulmann and Pell, 2010). Indeed, PD patients in the 
study of Kan at al. (Kan et al., 2002) performed better with video recordings than 
with photographs when asked to recognize sadness, anger, and disgust.  
The majority of studies included patients who were receiving dopamine replacement 
therapy (L-Dopa or dopamine agonists) and few selected patients who were not on 
treatment. Even among the studies using participants on dopamine replacement 
therapy, there could have been a fluctuation of the levels of the drugs, depending on 
the time of the latest intake of the medication in relation to the time of testing (Gray 
and Tickle-Denger, 2010). Indeed, many of the studies did not mention whether 
patients were at their ʺonʺ state during assessment. Four studies (Breitenstein et al., 
2001; Dujardin et al., 2004; Lawrence et al., 2007; Sprengelmeyer et al., 2003) 
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included patients, who were not receiving medication, either because they were 
early in the course of the disease or because they were  withdrawn from dopamine 
replacement treatment for the purposes of the study. In our study, all patients 
received their regular medication for the treatment of PD and were on their ʺonˮ 
state.  
Moreover, studies have varied in the extent to which PD patients have been 
matched with healthy control subjects on individual characteristics. For example, 
some studies have included among the PD groups individuals with significantly 
higher scores in the self-reported depression questionnaires than controls. As 
depression has been linked with deficits in the identification of emotions of faces 
(Feinberg et al., 1986), it is possible that these differences could have an influence 
on the results of the studies. Regarding depression, most of the studies have 
recruited participants, who did not have a psychiatric history, but only a few 
administrated a questionnaire of depression symptoms to the PD and control group, 
like in the present study (using the BDI). The majority of the studies matched the 
participants on age, gender and education, while a few studies matched only on age 
and education or age and gender alone. Regarding cognitive functioning, the 
majority of the studies excluded demented patients. One study (Beatty et al., 1989) 
(did not screen for dementia and) included patients with significantly lower score on 
the Mini-Mental State Exam than controls. In our study, the participants were age- 
and sex- matched and did not differ with respect to mini mental state examination 
score and education. The two groups in the present study differed in the depression 
score, which however did not influence the study results, as these were controlled 
for depression.  
One limitation of the study was the size of our sample which did not allow for 
rigorous regression analyses of many predictor factors simultaneously. Another 
limitation was the utilization of the subtests of the PANDA test to assess executive 
and visuospatial functions of the participants and not of more specific tests, to avoid 
increasing patients’ fatigability by already extensive neuropsychological testing. 
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The present study contributes to the efforts made to better characterize this 
increasingly recognized neuropsychiatric feature in PD and to understand closer the 
pathophysiology underlying the non-motor features of PD. Thus, the relevance of 
this study extents to the understanding of the pathophysiology disease, which is not 
yet clarified. Furthermore, the associations of facial emotion recognition with age 
and age of onset of PD shown in the present study, stress the importance of testing 
for this neuropsychiatric symptom in older groups of patients in the clinical praxis. 
The association of facial emotion recognition with olfaction shown in the present 
study, in particular, has not been reported before. This association is endorsed from 
common structures that undergo neurogeneration in PD and as olfaction is a well-
known pre-motor sign of the disease, it might be of interest for future studies to 
assess FER as a possible pre-motor sign of the disease with eventually contribution 
to the early-diagnosis of the disease.  
 
The degree of emotion recognition deficit appears to be correlated with other 
interpersonal difficulties, such as feeling of frustration in social interactions and this 
of social isolation (Clark et al., 2008). It is likely that reduced emotion recognition 
ability contributes to social stress and this can lead to acceleration of the progression 
of age-related diseases (Hawkley and Cacioppo, 2004). Recognizing accurately the 
emotional states of others is an essential component of successful social interactions 
and effective communication in interpersonal relationships (Blair, 2003). This 
highlights the importance of future research in this field. Therefore, it seems 
necessary to integrate tasks accessing facial emotion recognition in the clinical praxis 
in order to evaluate this non-motor aspect of the disease that can affect patients’ 
social behavior in order to appreciate the full extent of deficits of PD patients. Only 
with this holistic view of the patients and their deficits will be possible to provide an 
adequate treatment in PD. 
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Appendix  
Hoehn and Yahr scale 
The Hoehn and Yahr scale is a widely used scale for describing the progression of symptoms 
of Parkinson’s disease. It was originally published in 1967 in the journal Neurology by Melvin 
Yahr and Margaret Hoehn and included stages 1 to 5. Since then, a modified Hoehn and Yahr 
scale was proposed with the addition of stages 1.5 and 2.5 in order to describe the 
intermediate course of the disease. 
Stage Hoehn and Yahr Scale Modified Hoehn and Yahr Scale 
1 
Unilateral involvement only usually with 
minimal or no functional disability 
Unilateral involvement only 
1.5 - Unilateral and axial involvement 
2 
Bilateral or midline involvement without 
impairment of balance 
Bilateral involvement without 
impairment of balance 
2.5 - 
Mild bilateral disease with recovery on 
pull test 
3 
Bilateral disease: mild to moderate disability 
with impaired postural reflexes; physically 
independent 
Mild to moderate bilateral disease; 
some postural instability; physically 
independent 
4 
Severely disabling disease; still able to walk or 
stand unassisted 
Severe disability; still able to walk or 
stand unassisted 
5 
Confinement to bed or wheelchair unless 
aided 
Confinement to bed or wheelchair 
unless aided 
 
Modified Schwab and England Activities of Daily Living Scale 
 
100% – Completely independent. Able to do all chores without slowness, difficulty or 
impairment. Essentially normal. Unaware of any difficulty.  
 
90% – Completely independent. Able to do all chores with some degree of slowness, 
difficulty and impairment. Might take twice as long. Beginning to be aware of difficulty.  
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80% – Completely independent in most chores. Takes twice as long. Conscious of difficulty 
and slowness.  
 
70% – Not completely independent. More difficulty with some chores. Three to four times as 
long in some. Must spend a large part of the day with chores.  
 
60% – Some dependency. Can do most chores, but exceedingly slowly and with much effort. 
Errors; some impossible.  
 
50% – More dependent. Help with half of the chores, slower, etc. Difficulty with everything.  
 
40% – Very dependent. Can assist with all chores, but few alone.  
 
30% – With effort, now and then does a few chores alone or begins alone. Much help 
needed.  
 
20% – Nothing alone. Can be a slight help with some chores. Severe invalid.  
 
10% – Total dependent, helpless. Complete invalid.  
 
0% – Vegetative functions such as swallowing, bladder and bowel functions are not 
functioning. Confined to bed. 
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